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ABSTRACT 
 
ANGIOSTATIN LIKE PEPTIDES IN MILK: POTENTIAL DEVELOPMENT FOR 
DAIRY PRODUCTS CAPABLE OF CANCER PREVENTION 
 
Erin Stefanutti 
 
For the past 40 years, antiangiogenic approaches have been of major interest in 
the development of methods to cure and prevent cancer. Angiogenesis, the development 
of blood vessels from pre-existing vascularization, is essential for cancer growth and 
spread of metastasis through the delivery of nutrients and oxygen essential to sustain the 
metabolic activity of these malignant cells. Blocking access to blood will cause cancerous 
cells to assume a dormant state creating inactive micro-tumors innocuous to the host. 
Angiostatin, the internal fragment of the fibrinolytic zymogen plasminogen, has shown 
great potential in reducing cancer size and number of metastatic colonies in animal 
models. Owing to the success of these preliminary results angiostatin is currently on 
clinical trials. Plasminogen is known to be transferred from blood to milk during 
lactation. The objectives of this research were to: 1) investigate the ability of various 
proteases in cleaving plasminogen, both from human and bovine sources, and 
consequently release the angiostatin like fragment; 2) determine the anticancer activity of 
bovine angiostatin; 3) examine ability of the antiangiogenic fragment to survive 
digestion; 4) purify the fragment of interest through column chromatography. Production 
of angiostatin was tested through hydrolysis of plasminogen via Bacillus Polymyxa 
protease (or dispase I), elastase, lactic acid bacteria and Bacilli originated enzymes. Once 
proteases capable of angiostatin like peptide production were identified, and sequence 
analysis of the fragments obtained conducted to confirm that bovine angiostatin was 
indeed produced, ability of angiostatin, both human and bovine, in inhibiting malignant 
melanoma as well as colon cancer cells was evaluated in vitro. From the results obtained 
we can confirm that bovine angiostatin inhibitory activity on cancerous cells is similar to 
that observed for human angiostatin. Analysis of bovine angiostatin survival through in 
vitro human digestion model was also examined. Results show good possibility of 
angiostatin surviving digestion, even if confirmation of these results is required through 
further in vivo studies. Additionally, digestive enzymes such as trypsin and α-
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chymotrypsin showed ability in cleaving plasminogen directly to release a 25kDa 
fragment. Knowing that each kringle has some degree of anticancer activity it would be 
of interest to further study the possibility of angiostatin related fragments to be produced 
during milk digestion. Finally, affinity chromatography through L-lysine used to purify 
human angiostatin resulted to be an adequate method for bovine angiostatin purification. 
Preliminary results obtained from this study open a new area worth investigating to 
uncover the potential of using bovine angiostatin in the development of novel food 
products capable of cancer prevention.     
 
Key words: angiostatin, plasminogen, proteases, angiogenesis.    
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I. LITERATURE REVIEW 
 
1.1 BACKGROUND 
 
1.1.1 CANCER: A GENETIC DISEASE 
 
Cancer is a disease that has been affecting humans throughout their history. In 
ancient Egypt and Greece individuals would attempt to cure this disease, defined by 
Hippocrates as having a crab like shape, from there the name “cancer”, with magical 
spells or other sorcery tricks. Over the years cancer has gradually seen an increase in the 
number of individuals affected by this disease. This increase has been enabled by changes 
in our habits and in the environment in which we live today; examples are our diet, 
radiations and chemical exposure, etc. Moreover since cancer has a positive correlation 
with age, increase in longevity has resulted in a parallel increase in cancer cases. 
Nowadays cancer is the second leading cause of death in the United States and other 
economically developed countries (The history of cancer 2010; Landau Elizabeth 2010). 
Due to the severity with which this disease is affecting our society (one in five of us will 
die of cancer), scientists all over the world have been conducting extensive research to 
comprehend the origins of cancer in order to develop effective therapies (Alberts Bruce et 
al. 2008).   
After more than 25 years of research, cancer has revealed to be a disease that 
initiates at the genomic level through a sequence of events that will irreversibly convert a 
normal cell into a malignant one (Hanahan Douglas et al. 2000; Alberts Bruce et al. 
2008). Commonly, the first incident responsible for this alteration consists in an 
aberration on the hereditary information, genetic or epigenetic, of a single cell. 
Subsequently, through cell division, this anomalous trait gets transferred and accumulates 
in its progeny (Alberts Bruce et al. 2008). Succeeding cell cycles will then cause these 
cells to evolve assuming additional mutations that buildup in different genes overtime, 
promoting cancerous cells growth and tumor development (Alberts Bruce et al. 2008).  
Accretion on the number of occurring mutations will enable cells to evolve and 
adapt to a new environment. These will gain growth and survival advantages compared to 
normal cells. Conditions inside a tumor are characterized by low oxygen and nutrients 
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availability as well as growth barriers by presence of surrounding tissue; only evolved 
cells are able to survive in such harsh environment (Gatenby Robert A. et al. 2004; 
Alberts Bruce et al. 2008).  
According to Hanahan et al., six major traits are acquired during the transition of 
a cell from normal to cancerous: self-sufficiency in growth signals, insensitivity to 
growth inhibitory signals, evasion of programmed cell death, limitless replicative 
potential, sustained angiogenesis, tissue invasion and metastasis (Hanahan Douglas et al. 
2000).  
It is also true that different cancers should be considered as different diseases, 
since based on their origin and nature they will present different characteristics. In fact, a 
treatment may be very effective in inhibiting a specific tumor but useless for treating 
others. Nevertheless, there is no doubt that the majority of deadly cancers are those prone 
to evasion and metastasis which is favored and enabled by angiogenesis (Folkman Judah 
2006; Alberts Bruce et al. 2008).     
 
1.1.2 ANGIOGENESIS 
 
Angiogenesis is the process by which new blood vessels develop from pre-
existing vascularization. Angiogenesis is divided into physiological and pathological, 
which depends on whether angiogenic regulators‟ activity is controlled or fail to respond 
to specific signals (Judah Folkman  et al. 1992; Losso Jack N. 2003).  
Physiological angiogenesis is essential for reproduction, wound repair and tissue 
development, and is controlled by a balance between stimulators and inhibitors (Judah 
Folkman  et al. 1992; Losso Jack N. 2003). In fact, when specific tissues are under 
hypoxia conditions they will generate particular signals that will stimulate angiogenesis 
and will allow the development of blood vessels necessary for the transport of oxygen 
and nutrients to satisfy cells‟ need. Once the tissue has received enough oxygen required 
for cells metabolism, such cells will reduce the amount of angiogenesis stimulators 
produced and will start expressing antiangiogenic factors that will cause the capillary 
vessel previously formed to stop growing or degrade (Liekens Sandra et al. 2001).  
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On the other hand, during pathological angiogenesis, once angiogenic factors are 
stimulated and released by cells (i.e.: cancerous cells) they won‟t produce enough 
antagonists to bring back the equilibrium between anti- and pro- angiogenic factors, 
causing endothelial cells (EC) to be constantly stimulated. This phenomenon is known as 
the “angiogenic switch”. Once the switch is ON, development of numerous blood vessels 
that will support the growth of cancerous cells by continuously provide nutrients and 
oxygen is inevitable (Hanahan Douglas et al. 1996; Bergers Gabriele et al. 2003). Thanks 
to this mechanism, tumor cells are able to grow, proliferate and escape into the 
circulatory system where they are transported to distant sites causing metastasis to arise 
(Judah Folkman  et al. 1992). 
Many degenerative diseases are stimulated or affected by angiogenesis both 
through insufficient or excessive development of blood vessels. For example, insufficient 
blood supply may lead to heart disease, infertility and stroke. Conversely excessive 
angiogenesis may function as Parkinson‟s and Alzheimer‟s disease promoter, can cause 
complications in diabetic patients leading to blindness and may represent an obstacle in 
the cure of many other disorders (Losso Jack N. 2003).  
After many years of research, angiogenesis suppression is now recognized as a 
convincing strategy to suppress cancer growth and metastases (Hanahan Douglas et al. 
1996; Nelson Nancy J. 1999; Kerbel Robert S. 2000). In fact, many studies have 
confirmed that tumors cannot grow beyond their critical size (≈1-2 mm diameter) at 
which simple diffusion of nutrients and waste products is limited; without further blood 
supply tumor cells may become necrotic and/or apoptotic (Hanahan Douglas et al. 1996; 
Zetter Bruce R. 1998; Kerbel Robert S. 2000). Owing to these results, angiogenesis 
suppression represents a promising approach in many areas of cancer research and 
possible treatment development (Kerbel Robert S. 2000).  
  According to Folkman and Kalluri, many individuals carry microscopic non 
angiogenic in situ tumors that do not progress over time. Only 1 every 600 malignancies 
will switch towards an active state (angiogenic switch is activated) and grow into a 
detectable tumor (Folkman Judah et al. 2004; Folkman Judah 2006).  
From this observation it is possible to conclude that if tumors have no access to 
blood supply, and consequently to oxygen and nutrients, they will remain in a dormant 
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state (the number of cells proliferating equals the number of cells dying) for an undefined 
period of time and are harmless to the host. It is believed that endogenous angiogenesis 
inhibitors originally present in our organism (i.e. angiostatin), control and help maintain 
those micrometastases in a quiescent state (Folkman Judah et al. 2004). In fact a study 
conducted by Soff et al. in 1999 has shown that angiostatin can occur naturally in human 
plasma at concentrations of 6-12nM, perhaps enough to inhibit these micro-tumors to 
develop, however more research is required to confirm such statement (Soff Gerald A. et 
al. 1999).  
 
1.1.2.1 FACTORS INVOLVED IN ANGIOGENESIS INITIATION 
 
Angiogenesis is a very complex process involving numerous factors that interact 
through different mechanisms, which  makes it challenging for researchers to exactly 
understand the process and effectively find a way to block tumor vascularization 
(Hanahan Douglas et al. 1996; Cao Yihai 2004).  
Additionally, in order for the capillary to form and protrude from the pre-existing 
vessel many steps are required: EC proliferation and migration, basement membrane 
disruption, EC invasion of the surrounding stroma, and lumen formation through cells 
adhesion (Hanahan Douglas et al. 1996; Ji Weidong-richard et al. 1998; Cao Renhai et al. 
1999; Carmeliet Peter et al. 2000). Contrarily to normal blood vessels, tumor vessels are 
characterized by high disorganization and poor structure.  Moreover, these chaotic 
vessels present dead ends, are leaky and arterial blood mixes with venous blood 
(Carmeliet Peter et al. 2000; Wahl Miriam L. et al. 2004).     
Numerous angiogenic factors have been identified so far. Particularly of interest 
are VEGF (vascular endothelial growth factor), bFGF (basic fibroblast growth factor), 
angiopoietin and MMPs (metalloproteinases), which are overexpressed during tumor 
development. However, VEGF is known to be the most specific angiogenic factor since it 
only targets blood EC,  and experiments conducted on mice showed that inhibition of 
VEGF caused complete halt of tumor growth (Cao Yihai 2004). For this reason many 
drugs designed to treat cancer act on this molecule by inhibiting the interaction of VEGF 
with its receptors found on the surface of endothelial blood cells (Cao Yihai 2004). 
Avastin (also known as bevacizumab) for example, was the first antiangiogenic therapy 
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approved by the FDA, that consists of a recombinant humanized monoclonal IgG1 
antibody that recognizes and binds to VEGF blocking its biological activity (Ferrara 
Napoleone et al. 2005; Folkman Judah 2006; Genentech 2008). Avastin is now used to 
treat lung, kidney, colorectal and brain cancer in combination with chemotherapy or other 
drugs.    
1.1.2.2 VEGF ANGIOGENESIS SIGNALING PATHWAYS 
 
  As previously mentioned, VEGF has a central role in angiogenesis development. 
Many experiments show that VEGF is indispensable in both physiological and 
pathological processes. Particularly interesting were the results obtained from a study, 
where the removal of a single VEGF allele caused mice embryos death after only a few 
days of pregnancy, indicating that VEGF has a crucial role in proper vascular system 
development (Liekens Sandra et al. 2001; Dulak J. 2005). VEGF acts by interacting with 
its two tyrosine kinase receptors (VEGFR1 and VEGFR2) located on the surface of ECs. 
This contact activates numerous signaling pathways that will allow such cells to 
proliferate, differentiate, migrate, survive and consequently generate blood vessels 
(Zachary I. 2003). 
The expression of this pro-angiogenesis factor is mostly stimulated by hypoxia 
conditions, which in case of cancer are achieved when the tumor reaches its critical size 
of 1-2 mm in diameter. Several of the signals activated from the interaction between ECs 
receptors and VEGF are outlined in Figure 1. First, the survival signaling pathway is 
promoted by the activation of an anti-apoptotic kinase (akt) through phosphoinositide 3‟-
kinase pathway, which results in the phosphorylation and inhibition of a pro-apoptotic 
protein known as Bad. Instigation of this pathway will inhibit ability of activated ECs to 
undergo apoptosis that will consequently be kept active even after the signal stimulus 
cease.  
A second important pathway activated by VEGF when in contact with its 
receptors is known as the mitogenic signaling (Zachary I. 2003). This cascade response is 
driven by the MAPKs (mitogen activated protein kinases) pathway that leads to the 
activation of ERK (extracellular-signal-regulated protein kinases) as a final compound. 
ERK travels then into the nucleus of the ECs where it will phosphorylate and activate 
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specific gene regulatory proteins responsible for the expression of cell cycle initiators, 
such as G1 cyclins (Alberts Bruce et al. 2008).  
Another pathway, known as chemotactic signaling, plays also an essential role in 
promoting angiogenesis. This pathway stimulates cells‟ migration through FAK (focal 
adhesion kinase) activation; this kinase is involved in cell junction and its activation will 
cause loss of cell adhesion allowing cells‟ to migrate (Alberts Bruce et al. 2008).  Lastly, 
a less well understood pathway involves generation of nitric oxide and prostanoids (PGs) 
which are released outside the cell and will interact with other neighboring cells allowing 
vascular permeability regulation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: VEGF interaction with endothelial cells and activated signaling pathways 
(Zachary I. 2003) 
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1.2 ANGIOSTATIN 
 
1.2.1 THE DISCOVERY 
 
Angiostatin is one of the most potent angiogenesis inhibitors known to date 
(O'Reilly Michael S. et al. 1994; Cao Renhai et al. 1999). This molecule is obtained 
trough hydrolysis of plasminogen (PG), the zymogen of the fibrinolytic enzyme plasmin 
(PL) (O'Reilly Michael S. et al. 1994; Ji Weidong-richard et al. 1998; Wahl Miriam L. et 
al. 2005). This antiangiogenic peptide was discovered in the Folkman‟s lab in 1994 by 
O‟Reilly et al. while conducting research on the effects of primary tumors in inhibiting 
the development of metastasis as well as secondary tumors at distant sites (O'Reilly 
Michael S. et al. 1994; Zetter Bruce R. 1998; Cao Renhai et al. 1999; Soff Gerald A. 
2000). At that time, cancer researchers were trying to understand why the removal of 
some primary tumors caused rapid development of remote metastasis (O'Reilly Michael 
S. et al. 1994; Zetter Bruce R. 1998; Figg William D. et al. 2008). O‟Reilly et al., trough 
a sequence of experiments discovered that tumors were not only producing angiogenesis 
activators but also angiogenesis inhibitors. These experiments consisted in implanting 
Lewis lung carcinoma in mice, and once the tumor reached a size of 1 to 2 cm
3
, it was 
resected and growth of secondary and metastasis were examined (Figg William D. et al. 
2008). From the results collected in the study, it was evident that removal of the primary 
tumor caused considerable increase in the rate at which distant site cancerous colonies 
grew compared to control mice for which the primary tumor was not removed (O'Reilly 
Michael S. et al. 1994; Figg William D. et al. 2008). Additionally, resected mice 
developed high vascularization at the malignant sites contrarily to control mice which 
developed only microscopic metastases or small colonies of tumor cells, but no signs of 
neovascularization were observed (O'Reilly Michael S. et al. 1994). It is from these 
observations that the idea of the primary tumor producing an angiogenesis inhibitor 
capable of impeding ECs proliferation at distant sites was considered. In fact, from 
another experiment conducted to prove the likelihood of this thought, serum and urine 
obtained from tumor-bearing mice, but not that of healthy mice, caused significant 
proliferation inhibition of ECs in vitro (O'Reilly Michael S. et al. 1994). Through further 
analysis, a 38 kDa protein, later called angiostatin, was purified and confirmed to be the 
  
8 
 
molecule responsible in inhibiting ECs activity (O'Reilly Michael S. et al. 1994; Figg 
William D. et al. 2008). Indeed, by way of additional experiments, angiostatin showed to 
be capable of  inhibiting ECs proliferation and migration in vitro, tumor angiogenesis in 
vivo as well as tumor metastasis in animal models (Figg William D. et al. 2008).   
Sequencing of this 38 kDa band by micro molecular techniques, revealed the 
peptide to belong to the internal four-kringles K1-K4 domains of PG (Figure 2).  
 
 
 
 
 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
The discovery that cancer could produce peptides that would inhibit its own 
growth and consequent survival was at first regarded with skepticism. Following 
investigations allowed clarification on this phenomenon, confirming that generation by 
cancerous cells of a molecule that interferes with their ability to grow and proliferate is 
Figure 2: Plasminogen Structure (Platanias Leonidas C. 2009). In red are indicated 
the regions of PG that need to be hydrolyzed in order to obtain angiostatin K1-4. 
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accidental (Wahl Miriam L.  et al. 2005). Tumor cells do not synthesize angiostatin, a 
gene coding for angiostatin does not exist. Alternatively, during expansion, cancerous 
cells release many proteases necessary to support their metabolism such as matrix 
metalloproteinases (MMPs), cathepsin and elastase that promote activation of pro-
angiogenic factors (Ji Weidong-richard et al. 1998; O'Reilly Michael S. et al. 1999; 
Morikawa Wataru et al. 2000; Cao Yihai 2004). These proteases subsequently interact 
with PG molecules, which are present at higher concentration near the tumor due to 
vascularization increase. Plasminogen is then cleaved and the four kringle structure 
belonging to angiostatin released (Vassalli J. D. et al. 1991; O'Reilly Michael S. et al. 
1994; Cao Yihai 2004). Surprisingly, many other antiangiogenic molecules are directly 
produced by the action of enzymes released by tumors such as endostatin, which is 
obtained by cleaving collagen XVIII by the action of elastase and cathepsin (Wen Wei et 
al. 1999; Geiger J. H. et al. 2004; Figg William D. et al. 2008).  
Angiostatic molecules, such as angiostatin, have longer half-life in circulation 
than proangiogenic molecules, this is why they are able to reach distant micrometastasis 
and inhibit their growth. Contrarily, at the site of the primary tumor, the amount of 
angiostatin produced is not high enough to counterbalance the predominating 
neovascularization signals (O'Reilly Michael S. et al. 1994; Wahl Miriam L.  et al. 2005).    
 
1.2.2 MOLECULAR STRUCTURE 
 
Angiostatin was initially identified as belonging to the four internal kringle 
domains of PG (residues 78-440). A kringle is a loop like structures stabilized by three 
disulfide bonds (O'Reilly Michael S. et al. 1994; Cao Yihai et al. 1996; MacDonald 
Nicholas J. et al. 1999; Cao Yihai 2004; Geiger J. H. et al. 2004). Although angiostatin 
was discovered as containing four kringles, we now know that different kringles 
combinations from PG, such as K1-3, K1-4, K1-5 and K5 alone, also exert 
antiangiogenic activity. Interestingly, each of these kringle combinations possesses 
different inhibitory activity on either the proliferation or migration of ECs, two major 
mechanisms required to initiate and sustain angiogenesis (Cao Yihai et al. 1996; Cao 
Yihai et al. 1997; Abad Marta C. et al. 2002). On the contrary, intact PG has shown to be 
ineffective in inhibiting any type of EC activity or tumor angiogenesis (O'Reilly Michael 
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S. et al. 1994; O'Reilly Michael S. et al. 1996).  Analysis of the structural elements of 
these five loops will help us recognize which characteristics may be responsible in 
conferring angiostatin its potent antiangiogenic activity.  
The five kringles are known to have lysine binding site (LBS), however their 
affinity for lysine varies. In fact when in presence of epsilon-amino caproic acid (EACA), 
a small molecule used to mimic affinity to lysine, K1, K4 and K5 show high binding 
interaction, while K2 affinity is significantly lower and K3 shows almost no attraction 
(Lerch P. G. et al. 1980; Geiger J. H. et al. 2004). It is this difference in lysine binding 
that explains the affinity of PL to fibrin (Lerch P. G. et al. 1980). However it is still 
uncertain whether this difference in LBS affinity could also explain the different ECs 
inhibitory activity among kringle domains (Abad Marta C. et al. 2002; Geiger J. H. et al. 
2004).     
Each kringle is characterized by a string of 80 amino acids, and sequence analysis 
between kringles has shown 50% homology (Ji Weidong-richard et al. 1998; Cao Yihai 
2004). It is important to mention that integrity of angiostatin is essential for this molecule 
to maintain its activity. If the kringle folding is lost and the disulfide bonds reduced, the 
molecule is no longer active (Cao Yihai et al. 1996; Ji Weidong-richard et al. 1998).  
Through NMR and X-ray crystallography, molecular characteristics of angiostatin 
K1-3, the most potent antiangiogenic form of the molecule, were determined (Abad 
Marta C. et al. 2002).  Abad at al. defined angiostatin K1-3 as having a bowl like 
structure (Figure 3), with the kringle domains on the side of the bowl and the bottom 
represented by interkringle peptides (Abad Marta C. et al. 2002). The structure is 
maintained by many kringle/kringle and kringle/interkringle interactions. And 
interestingly a large cleft is observed between K2 and K3. Abed et al. believe this cleft to 
have a major role in recognizing specific ligands or sequences responsible for inhibiting 
ECs migration. In fact K2-K3 alone has shown to be a potent EC migration inhibitor 
(however no effect on EC proliferation was observed) (Abad Marta C. et al. 2002; Geiger 
J. H. et al. 2004).  
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Figure 3: Angiostatin K1-3 molecular structure. K1, orange; K2, pink; K3, light blue 
(Abad Marta C. et al. 2002)   
 
Another interesting fact regards the motility of the molecule. No direct linkage is 
observed between the three kringles allowing the molecule to orient its kringles towards 
their respective receptors, perhaps explaining why K1 alone has better proliferation 
inhibition activity while K2-K3 is a better migration inhibitor (Ji Weidong-richard et al. 
1998; Abad Marta C. et al. 2002; Geiger J. H. et al. 2004).   
Although a lot of research on the subject has been conducted much remains to be 
elucidated in order to understand the exact mechanism behind angiostatin-EC interaction, 
the receptors involved and the motifs or structure of angiostatin responsible for its 
anticancer activity.   
 
1.2.3 MECHANISM OF ACTION  
 
As previously mentioned, angiostatin is a strong angiogenesis inhibitor capable of 
inhibiting ECs proliferation and migration. Table 1 summarizes the findings obtained by 
various scientists which work has significantly contributed to the comprehension of 
angiostatin activity. 
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Table 1: Plasminogen kringle domains and their respective activity in proliferation and 
migration inhibition of endothelial cells, binding to EACA, and tumor inhibition 
capability (Geiger J. H. et al. 2004).  
Kringle Proliferation Migration 
EACA binding 
(µM) 
Tumor 
Inhibitory 
activity 
K1  +  +/-  12 ? 
K2  +  +  560 ? 
K3  +  +  - ? 
K4  -  +  26 ? 
K5  +++  +  140 ++ 
K1-4  ++  +++  ++ ++ 
K1-3  +++  +/-  ++ ++ 
K2-3  -  ++  ++ ? 
No effect is shown by – , a marginal effect is shown by +/- , varying degrees of potency are shown 
by +, ++, +++, an unknown effect is shown as „?‟.  
 
1.2.3.1 MIGRATION VS. PROLIFERATION INHIBITION 
 
Angiostatin investigators have confirmed that various forms of angiostatin and 
individual kringles of PG have different inhibitory activity on the proliferation or 
migration of ECs. Tests on the ability of angiostatin to inhibit other non EC lines were 
also conducted. However, results were not relevant confirming angiostatin to be specific 
for ECs (Cao Yihai et al. 1996; Cao Renhai et al. 1999).  
In 1996 Cao et al. conducted a study in which they characterized the ability of 
different kringle domains of human angiostatin in inhibiting ECs proliferation (Cao Yihai 
et al. 1996). Until then, angiostatin was only defined as belonging to K1-4 of PG, yet Cao 
et al. showed that by hydrolyzing K4 from this molecule a more potent inhibitor was 
obtained. Angiostatin as K1-3 exhibited a much higher inhibitory activity, than K1-4. In 
order to inhibit the proliferation of ECs by half only 70nM K1-3 were needed, while 
twice as much K1-4, 135nM, were necessary to obtain the same outcome (Cao Yihai et 
al. 1996). Interestingly, when tested alone K4 did not seem to have any effect on the 
proliferation of ECs, making scientists think that its presence may be futile. Though, as 
we will see next, K4 has shown to be one of the most potent kringles inhibiting ECs 
migration (Ji Weidong-richard et al. 1998).  
Throughout their study Cao et al. made another significant finding. They 
discovered that PG kringle 5 alone and K1-5, have even stronger anti-proliferative 
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activity than K1-3. For K5 alone, a half maximal concentration of 50nM was necessary to 
reduce by half the proliferative activity of ECs (Cao Yihai et al. 1997; Cao Renhai et al. 
1999). On the other hand only 50pM were necessary to obtain the same effect by K1-5 
(Cao Renhai et al. 1999). Interestingly, similar results were observed when angiostatin 
K1-4 plus K5 alone were tested on ECs, indicating that angiostatin and K5 have a 
synergistic effect and may act through different mechanism of action (Cao Renhai et al. 
1999). Table 2 summarizes the kringles tested by Cao et al. during their study and the 
concentration needed for each of the fragments analyzed to obtain a half maximal 
inhibitory response.  
 
Table 2: Anti endothelial cell proliferation activity of angiostatin and plasminogen 
kringle fragments. Values represent the mean of concentration for a half-maximal 
inhibitory response. (Cao Renhai et al. 1999) 
Plasminogen Fragments IC50 Inhibition (nM) 
Kringle 1 320 
Kringle 2 n/a 
Kringle 3 460 
Kringle 4 No significant inhibition 
Kringle 5 50 
Kringle 2-3 n/a 
Kringle 1-3 70 
Kringle 1-4 (angiostatin) 135 
Kringle 1-5 0.05 
 
Another study conducted by Ji et al. in 1998, investigated the effects of PG 
kringles and angiostatin in inhibiting ECs migration, another key step in angiogenesis 
progression. From this study interesting results were observed, and contrarily to the data 
collected from ECs proliferation inhibition, some kringles that were thought to have no 
activity resulted to be the ones with higher anti migration effect, such as K4 (Ji Weidong-
richard et al. 1998). On the other hand, K1-3 had little to no effect in inhibiting EC 
migration. However, highest anti-migration effect was obtained by angiostatin K1-4 (Ji 
Weidong-richard et al. 1998).  
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1.2.3.2 ATP-SYNTHASE INHIBITION  
 
The precise mechanism through which angiostatin acts to impede the 
development of blood vessels has not yet been fully elucidated. Nevertheless, many 
researchers have shown that angiostatin may act by inhibiting the ATP-synthase pump, 
integrin αvβ3 or angiomotin located at the surface of ECs. Many other receptors on ECs 
have been examined, however ATP-synthase is the most studied and for which results 
have been more significant (Wahl Miriam L. et al. 2005).    
F1F0ATP-synthase was originally thought to be only located on the mitochondrial 
inner membrane. It was in fact regarded as a surprise when Moser and Pizzo in 1995 
discovered that ATP-synthase was indeed a receptor for angiostatin (K1-3 and K1-4). 
Further analysis ascertained the presence of active ATP producing ATP synthase on the 
surface of ECs (Moser Tammy L. et al. 1999; Moser Tammy L. et al. 2001; Gonzalez-
Gronow Mario et al. 2003).  Interestingly, ATP-synthase has been identified on the 
surface of some cancerous cells as well (Figg William D. et al. 2008). 
   ATP-synthase has the function of providing energy to the cell by synthesizing 
ATP from ADP using a proton
 
gradient across the membrane (Boyer Paul D. 1997; 
Alberts Bruce et al. 2008; Mowery Yvonne M. et al. 2009). Inhibition of this pump, 
impedes the escape of protons into the extracellular surroundings,  resulting in a lower 
intracellular pH as well as a reduction of extracellular ATP produced, ensuing in ECs 
reduced proliferation due to increased cell death (Figg William D. et al. 2008; Mowery 
Yvonne M. et al. 2009).     
Since ATP synthase has been found on the surface of many other cells lines one 
would question whether angiostatin would inhibit other cells, some of which may have 
essential roles in our body such as epithelial cells, fibroblasts, or ECs involved in 
physiological angiogenesis. The unique characteristic of angiostatin is that it shows 
higher interaction with ATP-synthase at low extracellular pH and almost no interaction at 
higher pH (Wahl M. L. et al. 2002; Figg William D. et al. 2008). Typically, the pH in 
normal tissues is between 7.2-7.6, while tumors have an extracellular pH of 5.6-7.6 
(Wahl Miriam L. et al. 2004; Chi Sulene L. et al. 2006; Figg William D. et al. 2008). 
Tumor acidosis is a hallmark of these cells‟ environment. Cancerous cells need to rely 
more on glycolysis as an adaptation to hypoxia conditions. This form of metabolism 
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results in higher release of lactic acid responsible for lowering the extracellular pH 
(Gatenby Robert A. et al. 2004).  
The intracellular pH nevertheless remains the same in both cancerous cells and 
ECs situated near/inside tumors. For this reason under such conditions ATP-synthase 
function is essential and its activity higher in order to maintain a normal pH inside the 
cell and allow its survival (Chi Sulene L. et al. 2006). By interacting and impeding ATP-
synthase activity under such critical conditions, angiostatin compromises the 
circumstances necessary for the survival of the cell.  
The same laboratory that discovered ATP-synthase to be present on the surface of 
ECs and to be a target for angiostatin, later discovered the ability of angiostatin to interact 
with ATP-synthase located on the surface of cancerous cells.  Reduced proliferation as 
well as cell death through necrosis (typical when ATP depletion occurs) resulted to occur 
in a similar manner to that observed for ECs (Chi Sulene L. et al. 2006). In fact, also in 
this situation angiostatin interaction with ATP-synthase was pH dependent (Chi Sulene L. 
et al. 2006).     
Furthermore, angiostatin proved to be more effective in inhibiting certain type of 
cancers, or cell lines of the same cancer, compared to others. This is because cancerous 
cells will express different levels of ATP-synthase. Chi and Pizzo observed that lung 
adenocarcinomas cells presented on their surface a much higher amount of this ATP 
producing enzyme than prostate cancer cells for example. On the other hand, among two 
prostate cancer lines PC-3 and 1-LN, the expression of ATP-pump also differed. 
Interestingly the line known to be more deadly (PC-3) resulted to express fewer ATP-
synthase. This phenomenon could perhaps explain PC-3 to have a higher capability of 
escaping into the circulatory system resulting in a highly metastatic and hostile form of 
cancer, since less susceptible to the action of angiostatin or other inhibitors factors (Chi 
Sulene L. et al. 2006).       
In the same way, it was also determined that tumors characterized by a more 
acidic extracellular environment are statistically more inclined to evasion, mutation and 
drug/chemotherapy resistance (Martínez-Zaguilán Raul et al. 1996).  
Summarizing the work conducted by numerous scientists through the years, it 
seems that ability of angiostatin in inhibiting angiogenesis or cancerous cells 
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development is mostly affected by the external pH of the cell as well as the number of 
ATP-synthase expressed by the cells. Based on these finding we can predict that 
angiostatin will have a different inhibitory effect on different types of cancers.   
 
1.2.4 ANIMAL MODELS RESULTS 
 
As soon as angiostatin was discovered and its potent activity in vitro uncovered 
with a lot of excitement and positivity, various animal models were designed with a high 
level of expectations.  
The first in vivo experiments were conducted by the Folkman‟s laboratory, in 
which various human tumors were implanted in mice and then treated with angiostatin 
(O'Reilly Michael S. et al. 1996). The results obtained were positively significant. 
Angiostatin inhibited: human breast carcinoma by 95%, colon carcinoma by 97% and 
prostate carcinoma by 100% (O'Reilly Michael S. et al. 1996). Surprisingly, angiostatin 
did not cause a reduction of the rate at which the cells proliferate, which remained the 
same, but it triggered a significant increase in the number of cells undergoing apoptosis. 
Tumors reached a dormant state, in which the number of cells proliferating is balanced by 
the number of cells dying (O'Reilly Michael S. et al. 1996). This state was maintained as 
long as angiostatin was administered; as soon as angiostatin was withdraw the levels of 
VEGF increased and angiogenesis was once again enabled (O'Reilly Michael S. et al. 
1996). In any of the cases analyzed toxicity was a concern, not even when angiostatin 
was administered at high doses.      
MacDonald et al. analyzed whether in vivo effect of K1-3 and K1-4 differed. 
They compared the ability of these two molecules in inhibiting the growth of lung 
metastases typical of melanoma B16-BL6. Their findings showed no significant 
difference among the two forms of angiostatin. Kringles 1-3 and 1-4 inhibited the growth 
of the metastatic colonies by 80% compared to the controls (MacDonald Nicholas J. et al. 
1999). Additionally, analysis of ECs also indicated a reduced number at the metastasis 
sites compared to controls.  
Interestingly, investigation on the half-life denoted K1-4 to require significant 
longer time to be excreted (9.1hours) than K1-3 (4.8 hours) (MacDonald Nicholas J. et al. 
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1999).  However, since the antitumor activity between K1-3 and K1-4 is similar, the 
explanation for a different half-life may be that K1-3 is more target specific than K1-4, 
but more research is required for this statement to prove valid (MacDonald Nicholas J. et 
al. 1999).   
 As previously mentioned, Cao et al. discovered that K5 alone had a higher in 
vitro EC inhibitory activity than angiostatin. However, when tested on animal models, K5 
did not produce the expected effect on tumor regression. Contrarily to in vitro results, 
angiostatin K1-4 had a higher antiangiogenic activity in vivo than K5. This was explained 
by the fact that being a small molecule, K5 is expelled by the body at a faster rate and 
consequently its half life is so short that K5 does not have enough time to interact with its 
target and exert its anticancer activity (Cao Renhai et al. 1999; Cao Yihai 2004).  
Since best inhibition of proliferating ECs was observed in vitro by the five kringle 
fragment of PG, K1-5 in vivo antitumor activity was also tested and compared to that of 
angiostatin in various animal models: ability to suppress primary tumor growth, tumor 
neovascularization, and mouse corneal neovascularization. Kringles 1-5 (55kDa) was 
produced through the action of PL. K1-5 showed significant reduction of tumor 
vascularization, primary tumor growth and metastasis development and a much lower 
concentration of K1-5 was required compared to angiostatin (Cao Renhai et al. 1999). 
However, K1-5 over time did not cause tumors to reach a dormant state, it only reduced 
their growth rate (Cao Renhai et al. 1999). It would be of interest to further analyze the 
effects of K1-5 in humans in order to determine the half-life of this molecule, and 
whether its activity can be comparable to that observed in mice. Of major interest was to 
discover that no signs of toxicity were observed in animals, even when they were treated 
at high doses, giving scientists hope for positive results in clinical trials, since side effects 
and adverse reactions represent one of the major barriers in drug development and FDA 
approval.      
 
1.2.5 CLINICAL TRIALS 
 
A phase I clinical trial to evaluate primarily safety and toxicity of angiostatin was 
conducted at Thomas Jefferson University. Eligible patients had advanced stage of cancer 
  
18 
 
and failed previous chemotherapy treatment. In this study, angiostatin was administered 
at concentrations ranging from 15–300 mg/m2/day daily for a period of two weeks 
followed by a week break. Results proved good toxicity profile and patients did not show 
significant side effects (Beerepoot Laurens V. et al. 2003). However, rapid increase of 
VEGF and fibroblast growth factor (FGF) occurred during the time angiostatin was 
withdraw (Wahl Miriam L. et al. 2004; Wahl Miriam L. et al. 2005). Also, angiostatin 
showed a reduced serum half-life, approximately 20 minutes. Unfortunately no 
significant inhibition on cancer growth was seen. Perhaps patients had a too advanced 
phase of the disease for angiostatin to be effective and also the size of the group analyzed 
may have been too small to produce significant data (Beerepoot Laurens V. et al. 2003; 
Wahl Miriam L. et al. 2004; Wahl Miriam L. et al. 2005).   
In a phase II clinical study conducted at Indiana University, angiostatin‟s anti-
tumor activity was tested in combination with chemotherapy treatment. Patients with a 
stage IV lung cancer were treated with chemotherapy and recombinant angiostatin (rhAS) 
at concentrations of 15 to 60 mg twice daily. Results obtained at the end of the study 
confirmed higher control rate of the disease in patients treated with both rhAS and 
chemotherapy compared to patients treated only with chemotherapy. Additionally, higher 
response was observed when rhAS was administered at the highest concentration of 
60mg dose (Kurup A. et al. 2006).  
From the clinical trials conducted to date on angiostatin, it was not possible to 
determine the maximum effective or safe dose due to its very low toxicity profile. 
However, its half life was proven to be very short. Based on these observations, if we 
were to treat patients with angiostatin, high doses and constant administration of 
angiostatin would be required, which would not be the best or ideal treatment for patients 
(Wahl Miriam L. et al. 2005). More research is require in order to determine whether 
angiostatin is indeed a possible candidate for development of future anticancer drug, 
which form and source (from other animals i.e. bovine) of this molecule is more active 
and if its activity is amplified if administered in combination with other treatments such 
chemotherapy or other anticancer drugs. 
A current ongoing phase I/II clinical trial, is testing ability of angiostatin from 
being generated directly in the body by administration of tissue plasminogen activator 
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(tPA), and the resulting effects on metastatic colonies growth inhibition when in 
combination with chemotherapy (www.clinicaltrials.gov).    
 
1.3       ANGIOSTATIN IN MILK 
 
Plasminogen is a molecule known to be present in the circulatory system of all 
animals. Bovine plasminogen (bPG), for example, gets secreted in milk. Understanding 
of the molecular characteristics of bPG and comparing these traits with that of hPG, 
would be of interest in order to determine whether bPG could also represent an effective 
human cancer inhibitor.   
 
1.3.1 TRANSFER OF PLASMINOGEN FROM BLOOD TO MILK 
 
Plasmin is one the most abundant enzymes in milk. This serine protease is 
associated with casein micelles and its proteolytic activity can be either detrimental or 
necessary to establish the quality of specific dairy products (Bastian Eric D. et al. 1996; 
Ozen Banu F. et al. 2003; Ismail B. et al. 2010).  
Initially it was thought that hydrolysis in milk was produced by psychrotrophic 
microorganisms, however further research lead to the discovery of an enzyme, PL, 
originally known to be present in blood, to be also responsible for some of this 
proteolytic activity (Bastian Eric D. et al. 1996).  
In order to determine if PL found in milk was the same as the one known to be in 
blood, sequence analysis of milk PG and PL was conducted. Results proved the two 
molecules to be identical to those in blood (Benfeldt Connie et al. 1995). Moreover, it has 
been proven that neither PL nor PG are directly produced by the mammalian cells 
(Bastian Eric D. et al. 1996). So how does PG end up in milk? A group of scientists 
determined PG to be transported from blood into milk through the mammary cell wall 
lining during milk production and involution. Plasminogen is secreted in milk at a much 
higher concentration than PL. In raw milk the PL and PG concentration is 0.1–0.7 mg/mL 
and 0.8–2.8 mg/mL respectively. The transfer of PG into milk is additionally affected by 
various factors such as stage of lactation, lactation number and mastitis. Interestingly, 
also other components of the plasmin system are found in milk and are responsible for 
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controlling the conversion of PG into PL (Politis I. et al. 1989; Bastian Eric D. et al. 
1996; Larson N. K. et al. 2006).   
 
1.3.2 THE PLASMIN SYSTEM   
Similarly to blood, PL belongs to a group of enzymes that together form the 
plasmin system (Figure 4). These enzymes comprise of: PG, PL, plasminogen activators 
(PA) (divided into tissue type (t-PA) and urokinase (u-PA)), plasminogen activators 
inhibitors (PAI) and plasmin inhibitors (PI). As their names indicate, the plasmin system 
interacts to promote or inhibit the proteolytic activity which is affected by milk 
processing and storage condition (Ismail B. et al. 2010).  
 
 
 
 
 
Figure 4: The plasmin system in milk (adopted from Bastian and Brown, 1996)   
   
Interestingly, the various PL system components have different thermal stabilities 
to different processing conditions. For example, PG and PL are resistant to high 
temperature processing. They completely survive pasteurization, and may also survive 
certain UHT and HTST treatments as well (Bastian Eric D. et al. 1996; Ismail B. et al. 
2010).  Plasminogen activators also have high heat stability, even higher than PG and PL, 
contrarily to PAI and PI that require only pasteurization temperatures to be inhibited. Due 
to the inhibition of the inhibitors while the activators are still functional, PG and PL 
activity is maintained during storage. Additionally, by heating PG over 50-60°C, causes 
the molecule to denature and consequently PA have more access to the molecule‟s 
structure and can easily activate PG (Burbrink C. N. et al. 2006; Ismail B. et al. 2010).   
Plasminogen 
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Plasmin 
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Casein 
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1.3.3 COMPARISON BETWEEN HUMAN AND BOVINE PLASMINOGEN 
 
In order to better understand some of the characteristics of bPG it would be useful 
to compare this molecule with human plasminogen (hPG). This will allow us to predict 
whether bPG could be used as a potential candidate for generation of peptides capable of 
anticancer activity, and how differences compared to hPG may cause this molecule to be 
more or less efficient.   
Schaller et al. compared the molecular structure of bPG and hPG. From this study, 
scientists were able to conclude that bPG and hPG have many similarities (Schaller J. et 
al. 1985). For example, they only differ in length by four amino acids (786 for bPG and 
790 for hPG). Bovine PG has a molecular weight of 88 kDa while hPG can either be 89 
or 91 kDa depending if a glycosylation site is present or not (Schaller J. et al. 1985; 
Bastian Eric D. et al. 1996). Over all, the two molecules share 78% homology; 
interestingly when this comparison is done only on the kringle region 83% homology is 
observed. This indicates that the internal triple-loop structure is maintained and is quite 
similar in both molecules (Schaller J. et al. 1985). Table 3 summarizes the percent 
homology among kringles and connecting strands between hPG and bPG.  
 
Table 3: Sequence analysis homology among individual kringles and connecting strands 
between human and bovine plasminogen (adopted from Schaller et al. 1985).   
Kringles Connecting Strands 
Kringles % Homology 
Connecting 
Kringles 
% Homology 
K1 75 K1/K2 33 
K2 88 K2/K3 92 
K3 83 K3/K4 54 
K4 90 K4/K5 42 
K5 81   
Overall Identity 83 Overall Identity 65 
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1.4       RESEARCH OBJECTIVES 
 
Knowing that PG is also present in milk, but for which ability of being 
hydrolyzed to release potential anticancer fragments has not been extensively studied to 
date, the objectives of this research were to: 1) investigate the ability of various proteases 
in cleaving plasminogen, both from human and bovine sources, and consequently release 
the angiostatin like fragment; 2) determine the anticancer activity of bovine angiostatin; 
3) examine ability of the antiangiogenic fragment to survive digestion; 4) purify the 
fragment of interest through column chromatography.  
Each of the following chapters will analyze a specific aspect of this work and will 
represent a potential publishable paper each independent from next.    
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II. ANGIOSTATIN GENERATION THROUGH BOVINE PLASMINOGEN 
HYDROLYSIS 
2.1 ABSTRACT 
 
Ability of various proteases in hydrolyzing bovine plasminogen (bPG) and 
releasing fragments in the 38 kDa range corresponding to angiostatin‟s molecular weight 
was analyzed. Enzymes such as elastase, Bacillus polymyxa protease (BPP) as well as 
Bacillus and Lactobacillus derived proteolytic enzymes were tested. Fragments generated 
during hydrolysis were first visualized and identified using sodium-dodecyl 
polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting methods of 
analysis. Subsequently, fragments of interest were analyzed for mass spectrum-based 
sequence analysis in order to identify the exact portion of plasminogen the fragments 
represented. From the results obtained we can confirm that at ideal enzyme-substrate 
ratio, B. polymyxa produce clear bands in the 40-34 kDa range both from human and 
bovine PG, that were confirmed to belong to internal kringles 1-4 region of PG. B. 
polymyxa showed higher affinity for the human substrate since 10 fold less concentrated 
enzyme (0.01 mg/ml compared to 0.1 mg/ml) was needed to generate the fragments of 
interest. Elastase, on the other hand, revealed higher interaction with the bovine source of 
the molecule, and the reaction resulted in clear bands at the molecular weight of interest 
and almost no generation of secondary products; this was contrary to all the other 
enzymes analyzed for which thick bands in the 50kDa area were seen. Moreover, most of 
the Bacillus species, but not Lactobacillus, showed ability in generating proteases during 
growth capable of hydrolyzing PG and generating smaller molecular weight fragments. 
Discovery of novel enzymes capable of angiostatin generation from bovine sources and 
with comparable structure to that of human angiostatin, may lead to the development of 
novel dairy products capable of cancer prevention.        
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2.2 INTRODUCTION  
 
The theory initially developed by Folkman in 1971, who believed that in order for 
tumors to grow beyond a specific size (1-2 mm) access to blood is indispensable to allow 
delivery of essential nutrients and oxygen necessary to support malignant cells‟ 
metabolism, is now widely accepted (Zetter Bruce R. 1998; Folkman Judah 2006). 
Various experiments have proven this supposition to be correct. Investigations have 
demonstrated that by blocking tumors access to blood, growth is inhibited. Malignant 
colonies are maintained in a dormant state, in which the number of cells proliferating is 
balanced by the number of cells dying (Cao Renhai et al. 1999; Folkman Judah 2006). If 
tumors are maintained at this size and are inhibited access to elements required for further 
growth, they can be innocuous to the host (Folkman Judah et al. 2004; Folkman Judah 
2006). The discovery that by blocking angiogenesis, the mechanism through which blood 
vessels develop from pre-existing vascularization in response to stimuli (i.e. hypoxia 
inducible factor released by cancerous cells), tumors cannot mature, opened a new area of 
investigation.  
Many molecules with antiangiogenic activity have been discovered, and 
antiangiogenic drugs, such as Avastin, have been approved by the FDA as effective 
cancer therapies (Folkman Judah 2006). Angiostatin, a peptide obtained through 
hydrolysis of fibrinolytic zymogen PG, discovered in 1994 resulted to be one of the most 
potent antiangiogenic molecules known to date. Heterogeneous proteases capable of 
generating this peptide, from enzymes released directly by cancerous cells such as 
cathepsin D to more exotic metalloproteinases found in snake venom, have been studied 
for their affinity for PG and for the difference in endothelial cells inhibition obtained by 
the action of the angiostatins generated by each enzyme (Morikawa Wataru et al. 2000; 
Ho Paulo Lee et al. 2002). Angiostatin, characterized by the first four internal kringles of 
PG, has shown ability in endothelial cell proliferation and migration inhibition as well 
primary tumor shrinkage and metastasis development prevention (O'Reilly Michael S. et 
al. 1994; Cao Yihai et al. 1996; O'Reilly Michael S. et al. 1996; Ji Weidong-richard et al. 
1998). Due to the success of these preliminary results, angiostatin is currently in clinical 
trials (Cao Renhai et al. 1999; Cao Yihai 2004; Wahl Miriam L. et al. 2004).  
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Interestingly bovine PG is also present in milk, since it gets transferred from 
blood during milk production via the mammary cell wall lining (Ismail B. et al. 2010). 
Comparisons between human and bovine PG was conducted and many structural 
similarities were identified (Schaller J. et al. 1985; Bastian Eric D. et al. 1996). However, 
anticancer activity of the internal molecular structure of bPG has not been extensively 
studied as yet. The objective of this research was to identify various enzymes capable of 
hydrolyzing bPG and release the four or three internal kringle domains corresponding to 
angiostatin. These reactions were conducted in buffer as well as in milk systems in order 
to evaluate possible differences due to the presence of other proteins. Enzymes such 
elastase (known to be able to generate human angiostatin), BPP (proven to be capable of 
plasmin hydrolysis through a study conducted by Larson et al. 2006), as well as Bacillus 
and Lactobacillus generated proteases were tested for bovine angiostatin generation. 
    
2.3 EXPERIMENTAL PROCEDURES 
 
2.3.1 REAGENTS AND SOURCES 
 
Bovine plasminogen (product # 416), human glu-plasminogen (product # 412) 
goat anti-bovine plasminogen (product # 3416) were purchased from American 
Diagnostica (Greenwich, CT). Angiostatin human, rabbit polyclonal antibody (product # 
RD 181056100) was purchased from BioVendor (Candler, NC). Dispase I (BPP) 
(product # D4818), elastase from human leukocytes (product # E8140) 3,3‟-
diaminobenzidine tetrahydrochloride hydrate (DAB) (product # D5637) and 6-
aminocaproic acid (product # A2504) were purchased from Sigma-Aldrich (St. Louis, 
MO). Peroxidase AffiniPure Goat Anti-Rabbit IgG (H+L) (product # 111-035-003) and 
Peroxidase Affinipure Rabbit Anti-Goat IgG (H+L) (product # 305-035-003) were 
purchased from Jackson ImmunoResearch Laboratories (West Grove, PA). The following 
electrophoresis and Western blotting reagents and materials were purchased from Bio-
Rad Laboratories (Hercules, CA): 40% Acrylamide/Bis solution (product # 161-0148), 
Coomassie Brilliant Blue R-250 Staining Solution (product # 161-0436), Precision Plus 
Protein All Blue Standards ( product # 161-0373),  12 and 18 wells Criterion empty 
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cassettes (product # 345-9901 and 345-9902), Tris/Glycine/SDS 10X (product # 161-
0772), Laemmli sample buffer (product 161-0737),  tetramethylethylenediamine 
(TEMED, product 161-0800), Bio-Dot/Bio-Dot SF Filter Paper (product # 162-0161) and 
Sequi-Blot PVDF 0.2 µm membrane (162-0184). Ammonium Persulfate (APS, product # 
BP179-100), Tween 20 (product # BP 337-500), Granular gelatin (product # G8-500) 
were purchased from Fisher Scientific (Hanover Park, IL). The strains of Bacilli and 
Lactobacilli used were from the Cal Poly DPTC collections.  
 
2.3.2 PART 1. Generation of angiostatin from bovine and human plasminogen 
hydrolysis by the action of Bacillus polymyxa protease 
 
2.3.2.1 Bacillus polymyxa protease interaction with bovine plasminogen  
 
In order to analyze the enzyme kinetics and determine the ideal enzyme-substrate 
ratio (E:S) for the generation of angiostatin like fragments, various concentrations of bPG 
and BPP were analyzed. Samples were prepared following Larson et al. (2006) procedure 
with adjustments. Both BPP and bPG were diluted in MTB (0.05 M Tris, 0.1M NaCl, 
0.01% Tween 80, pH 7.6) at a final concentration of 1mg/ml (27.78 μM and 11.36μM 
respectively) and stored at -20°C. In order to determine ideal enzyme concentration, BPP 
was first diluted in MTB to a final mg/ml of 0.025, 0.05, 0.075, 0.1, 0.125, 0.150 and 
0.175; subsequently BPP was incubated with 1mg/ml bPG at a 1:1 (v/v) ratio at 37°C for 
1 hour (Figure 5a). In a similar way, bPG was diluted in MTB to a final concentration of 
0.125, 0.25, 0.5, 0.75, 0.875 and 1mg/ml, and was then incubated at 37°C in 1:1 volume 
ratio with 0.1mg/ml BPP for 1 hour (Figure 5b). Once the ideal E:S was defined, 
progression of the hydrolysis as well as enzyme-substrate affinity and interaction was 
analyzed by collecting samples after 5, 10, 15, 20, 25, 30, 40, 50 and 60 minutes 
incubation. Prior to SDS-PAGE or western-blotting analysis, 1:1 (v/v) Laemmli sample 
buffer was added to samples collected to stop the reaction and boiled for approximately 5 
minutes to allow SDS binding. 
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Figure 5: Experimental design for determining ideal enzyme-substrate (BPP-bPG) ratio: 
A) ideal enzyme concentration determination; B) ideal substrate concentration 
determination.    
 
2.3.2.2 Temperature effect on Bacillus polymyxa protease and plasminogen interaction  
 
In order to evaluate the effects of temperature on BPP-bPG interaction, and 
determine if bPG denaturation will enhance its hydrolysis and consequent angiostatin 
release by the action of BPP, two experiments were conducted. In the first one, a solution 
of bPG (0.75 mg/ml or 8.52 μM) and BPP (0.1 mg/ml or 2.78 μM) at 1:1 (v/v) ratio was 
incubated directly at 4, 37, 70 and 90°C. In order to evaluate the progression of the 
reaction over time, samples were collected after 1, 5, 10, 15, 20, 25 and 30 minutes of 
incubation when tested at 4 and 37°C and after 1, 2, 3, 4, 5, 6 and 7 minutes for samples 
tested at 70 and 90°C (Figure 6a). These temperatures were chosen with the intention of 
simulating refrigeration, optimal, pasteurization and HTST conditions commonly used in 
the industry.  
On a second experiment, bPG alone was heated at 70°C for 7 minutes. This 
temperature is known to cause bPG denaturation. Subsequently, after causing bPG 
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tertiary structure to unfold, BPP was added to the solution at a 1:1 (v/v) ratio. Samples 
were immediately incubated in a water bath at 37°C, and collected at 1, 5, 10, 20, and 30 
minutes (Figure 6b). As a control, the enzyme was incubated with native bPG (not heated 
at 70°C prior to interaction with BPP) under the same conditions and procedures 
previously outlined.          
 
 
 
       
 
 
 
 
 
 
 
 
 
 
Figure 6: Experimental design on the analysis of temperature effects on the interaction 
between BPP and bPG: A) BPP-bPG interaction was conducted at 4°C, 37°C, 70°C and 
90°C; B) BPP affinity variation between native and denatured bPG.    
 
 Subsequently, the same experiment was repeated in milk in order to simulate 
conditions normally occurring in a milk matrix and evaluate potential differences with 
observations made when experiment is conducted in a buffer system. In brief, a 1:1 
volume solution of bPG (0.75 mg/ml, 8.52 μM) and UHT milk (previously diluted at a 
1:5 ratio in double-distilled water (ddwater)) was obtained and heated at 70°C for 7 
minutes. Controls were prepared following the same procedures but contrarily to 
treatments were not subjected to heating. Samples were then incubated with BPP (0.1 
mg/ml, 2.78 μM) at 37°C and collected at 1, 5, 10, 20 and 30 minutes after the beginning 
of the reaction. Laemmli buffer was added at a 1:1 volume ratio and samples were boiled 
for 5 minutes and analysis through gel electrophoresis was conducted.  
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2.3.2.3 Identification of angiostatin like fragments through SDS-PAGE, western blot and 
sequence analysis   
 
2.3.2.3.1 SDS-PAGE     
 
In order to analyze the molecular weight of the fragments obtained from the 
reaction between bPG and BPP, gel electrophoresis was conducted. The samples, 
prepared as previously described, and a molecular standard (range 10-250 kDa) were 
loaded in the wells of an 18 or 12 wells hand cast 15% tris-HCl gel. The gels were 
prepared following Laemmli (1970) adapted procedures (Laemmli U. K. 1970). 
Electrophoresis was conducted using a Criterion vertical midi-format electrophoresis cell 
(BioRad) at 200V for approximately 60 minutes, in SDS-PAGE running buffer (1:10 
dilution of Tris/Glycine/SDS 10X running buffer in ddwater). After electrophoresis, gels 
were stained in Coomassie blue (50% methanol, 10% glacial acetic acid and 0.25% 
Coomassie brilliant blue), for one hour in a shaker plate at room temperature. 
Subsequently gels were destained by overnight incubation in a 10% glacial acetic acid 
and 5% methanol solution. Gels were then analyzed, and the fragments of interest 
identified.      
 
2.3.2.3.2 WESTERN-BLOT 
 
  To ensure that the fragments of interest observed at 40kDa or lower molecular 
weight belong to the internal molecular structure of PG, western blot was conducted 
following Wang et al. (2006) procedures with some modifications. Samples were 
prepared as outlined in section 2.3.2.1 and loaded on a 15% Tris-HCl gel. Electrophoresis 
was conducted following procedures previously summarized in section 2.3.2.3.1. Once 
the pre-stained standard and protein samples were allowed to run through the gel, 
unimportant parts of the gel were cut off. In a trans-blot SD semi-dry transfer cell 
(BioRad) two filter papers were soaked in buffer A (Table 4) and placed on the surface of 
the anode plate of the cell. Subsequently, two additional filter papers were soaked on 
buffer B and placed on top of filter papers previously soaked in buffer A. At this point, a 
polyvinylidene fluoride (PVDF) membrane (pore size 0.2 µm), was cut to match the size 
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of the gel and then activated in methanol for 15 seconds. Afterwards, the membrane was 
rinsed in ddwater and subsequently placed on top of papers previously soaked on buffer 
B, ensuring that no air bubbles are trapped between the membrane and the filter paper. 
The gel was then placed on top of the membrane and subsequently covered with other 
four filter papers, previously cut to match the size of the gel and soaked in buffer C. 
Transfer was then effectuated at 20V and 40W for 15 min. At this point, the PVDF 
membrane was placed in a blocking solution of 3% gelatin (w/v) in PBS-Tween for one 
hour in a shaker plate at room temperature. Next, the membrane was washed three times 
for five minutes with PBS-Tween, and subsequently the primary antibody (goat anti-
bovine PG 1:2000 dilution in PBS-Tween, Wang et al., 2006) was added and the gel was 
placed in a shaker for 2 hours at room temperature. The washing step was repeated prior 
to incubation with the secondary antibody (peroxidase-conjugated AffiniPure rabbit anti-
goat IgG (H+L) 1:5000 dilution in PBS-Tween, Wang et al., 2006) which was conducted 
for 1 hour at room temperature in a shaker plate. After incubation with the secondary 
antibody, the membrane was washed again three times with PBS-T for 5 minutes. The 
developing solution was prepared by diluting 12 mg of 3,3‟-diaminobenzidine 
tetrahydrochloride hydrate, in 20 ml of tris buffered saline (TBS) and 25 µl of 30% 
hydrogen peroxide, and was then added to the membrane right after the last washing step. 
Once the desired color on the membrane was obtained, and bands of interest visible, the 
reaction was stopped by addition of ddwater. The membrane was allowed to dry by 
placing it over night in between two filter papers.  
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Table 4: Buffer recipes and preparation for western blotting 
 
 
2.3.2.3.3 SEQUENCE ANALYSIS OF BANDS OF INTEREST  
 
Once bands of interest were detected after SDS-PAGE and western blotting 
analysis, sequence analysis was conducted through liquid chromatography-mass 
spectrometry (LCMS) in order to identify the portion of PG the fragments obtained 
belong. By ensuring no contamination of the reagents used, samples were prepared and 
allowed to run normally on SDS-PAGE as outlined in section 2.3.2.1 and 2.3.2.3.1. Once 
the gel was obtained, the bands of interest were cut and placed in Eppendorf tubes 
Phosphate Buffered Saline (PBS, 20 mM PBS) 
1.38 g sodium phosphate monobasic 
2.68 g sodium phosphate dibasic 
8.5 g NaCl 
Dilute to 1 L with DDW 
PBS-Tween 
1 L PBS (20 mM) 
5 mL Tween 20 
PBS-Tween +3% gelatin (100 ml) 
            100 ml PBS-Tween 
3 g gelatin  
Heat solution while stirring at 70°C for 30 minutes. Turn off heat and 
continue stirring for 1 hour 
Buffer A (250 ml) 
            9.085 g Tris Base (0.3 M) 
            Adjust to pH 10.4  
Buffer B (250 ml) 
            0.76 g Tris Base (0.025 M) 
            Adjust to pH 10.4  
Buffer C (250 ml) 
            0.76 g Tris Base (0.025 M) 
            1.312 g 6-amino-n-hexanoic acid (0.4 M) 
            Adjust to pH 9.4 
Tris Buffered Saline (TBS, 0.5 mM Tris, 150 mM NaCl) 
0.6 g Tris base 
0.87 g NaCl 
Dilute to 100 mL with DDW 
Adjust to pH 7.6 with HCl 
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containing destain solution (10% acetic acid, 5% methanol) and sent to UC Davis 
proteomics core for LCMS analysis.  
 
2.3.2.4 Bacillus polymyxa protease ability in generating human angiostatin  
 
Similarly as for bPG, ideal E:S concentration was investigated between hPG and 
BPP in order to determine conditions for highest angiostatin yield and to compare the 
affinity of the enzyme between human and bovine substrates. In this case, two 
concentrations of BPP (0.01 and 0.025 mg/ml) were tested in a 1:1 volume ratio with 
hPG (1mg/ml, 11.36 μM). The reaction was conducted at 37°C and samples were 
collected after 0, 1, 11, 21, 31, 41, 51 and 61 minutes incubation when tested with BPP at 
a concentration of 0.01mg/ml, or after 0, 5, 10, 15, 20, 25 and 30 minutes for samples 
treated with 0.025mg/ml of BPP. All samples were diluted with Laemmli buffer (1:1 v/v 
ratio) and boiled for approximately 5 minutes. Subsequently samples were analyzed 
through SDS-PAGE following procedures outlined in section 2.3.2.3.1. 
  
2.3.2.4.1 WESTERN –BLOT 
 
Western blotting procedures were conducted as described in section 2.3.2.3.2. 
However, the primary antibody, Angiostatin Human Rabbit polyclonal antibody, was 
used at a 1:5000 dilution in PBS-T and the secondary antibody, Peroxidase-conjugated 
AffiniPure Goat Anti-Rabbit IgG was used at a 1:10000 dilution in PBS-T according to 
the manufacturer indications. 
  
2.3.3 PART 2. Generation of angiostatin from bovine and human plasminogen 
hydrolysis by the action of elastase 
 
2.3.3.1 BOVINE ANGIOSTATIN GENERATION 
 
In order to generate angiostatin from bovine plasminogen, elastase at a 
concentration of 0.01 mg/ml (345 nM) was incubated with bPG 1 mg/ml (11.36 μM) at a 
1:1 volume ratio. The reaction was conducted at 37°C for 1, 2, 4, 6 and 8 hours. Samples 
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were then diluted with Laemmli buffer at 1:1 volume ratio and boiled for 5 minutes. 
Fragments produced from this reaction were identified through SDS-PAGE and western-
blot as explained in sections 2.3.2.3.1 and 2.3.2.3.2.    
 
2.3.3.2 HUMAN ANGIOSTATIN GENERATION 
 
The ability of elastase in hydrolyzing hPG was tested in a similar manner as for 
bPG. Elastase (0.01 mg/ml, 345 nM) was incubated with hPG (1 mg/ml, 11.36 μM), at 
37°C for 30 minutes, 1, 2, 4, 6 and 8 hours. Samples were then diluted 1:1 (v/v) with 
Laemmli buffer, boiled for 5 minutes and then analyzed through SDS-PAGE (refer to 
section 2.3.2.3.1) and western-blot (refer to section 2.3.2.3.2).   
2.3.4 PART 3. Generation of angiostatin from bovine plasminogen hydrolysis by the 
action of Bacillus and Lactobacillus originated proteases 
 
Various lactic acid bacteria (LAB) and Bacillus strains were tested for their ability 
in producing proteolytic enzymes that were later examined for their ability in interacting 
with bPG to generate potential angiostatin fragments. Additionally, since bacteria 
expression of inducible genes is affected by the composition of the environment in which 
they are grown, the effect of different substrates and their influence on bacteria growth 
and proteolytic enzyme expression and release were analyzed. Summary of the 
experimental design is shown in Figure 7 and 8.  
 
2.3.4.1 LACTOBACILLUS PROTEASES GENERATION ANALYSIS 
 
Various Lactobacilli strains were tested for their capability in generating 
proteases with potential ability in interacting and cleaving bPG. Lactobacilli were grown 
in three different media and consequent proteolytic activity examined through skim milk 
agar plates.  
First, various strains of Lactobacilli, some of which we knew from the literature 
to be highly hydrolytic such as L. helveticus, or commonly used in the production of 
cheese such as L. acidophilus (Salimen Seppo et al. 1998), were grown in 10 ml MRS 
(5.5% MRS, 0.05% cysteine solution autoclaved at 121°C for 15 minutes (De Man J. C. 
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et al. 1960)) overnight at 37°C in a CO2 chamber. Subsequently, 100 µl of each bacteria 
were transferred into falcon tubes containing 10 ml of either 20% NFDM solution, UHT 
milk or MRS containing 1% skim milk (Figure 7), and allowed to grow overnight, always 
at 37°C in a CO2 chamber. Meanwhile, skim milk agar plates were prepared (10% v/v 
skim milk, 1.5% w/v agar solution autoclaved at 121°C for 15 minutes and poured 20 ml 
into Petri dish plates (Maunsell Blaithin et al. 2006) ). After bacteria were allowed to 
grow and skim milk agar solidified, sterile filter paper disks (5 mm diameter) were 
arranged on the surface of each agar plate. Fifteen µl of each bacteria-containing media 
were carefully added to one of the filter paper disk. These procedures were conducted in 
triplicates. Plates were incubated over night at room temperature. The proteolytic activity 
was quantified by measuring the visible zone of clearance surrounding the filter paper 
disk. If proteases were produced by the microorganisms and capable of hydrolyzing the 
surrounding casein, a clear halo would be observed around the filter disk, on the contrary 
if no proteolytic activity occurs, the area of interest would remain white.  
 
 
 
 
 
 
Figure 7: Experimental design to determine Lactobacillus proteolytic enzymes generation 
in different growth media. 
 
2.3.4.1.1 PROTEASES INTERACTION WITH BOVINE PLASMINOGEN 
 
It is known that LAB produce two types of proteases: extracellular or cell wall 
associated. These enzymes are needed by the microorganisms to hydrolyze bigger 
proteins that the cell will then uptake and use as a source of peptides and amino acids for 
metabolic purposes (Salimen Seppo et al. 1998). After analyzing which media and which 
strains resulted in higher generation of proteases, Lactobacilli were grown again under 
ideal conditions and the solution to be analyzed for enzymes activity was incubated with 
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bPG. A series of experiments were conducted in order to determine whether the 
proteolytic enzymes released outside the cell or associated with the cell wall of the 
microorganism, showed ability in bPG hydrolysis. Analysis of the products obtained 
from this reaction was conducted through SDS-PAGE as described in section 2.3.2.3.1. 
Since best hydrolytic activity observed in skim milk agar plates resulted for 
microorganisms grown in UHT milk and MRS-1% skim milk, these media were used to 
test for bPG hydrolytic enzymes.  
After inoculating UHT milk with each microorganism, and allowed Lactobacilli 
to grow overnight, 1 ml of UHT milk after inoculation was transferred into a 1.5 ml 
Eppendorf tube. Samples were centrifuged at 10 rpm between 5 and 10 minutes until a 
clear supernatant was observed. The supernatant obtained after centrifugation, was added 
to bPG (1mg/ml, 11.36 μM) at a 1:1 volume ratio and allowed to interact for 3 hours at 
37°C. After 3 hours the reaction was stopped by addition of Laemmli buffer solution (1:1 
volume ratio) and samples were boiled for 5 minutes and analyzed through SDS-PAGE. 
Due to UHT high protein content, it was not possible to use this media to test for 
the cell wall associated enzymes ability in interacting with bPG since high dilutions were 
needed prior or after interaction with the substrate, causing poor results through 
electrophoresis analysis. In order to be able to have a better understanding on the ability 
of either extracellular or cell wall bound proteins in hydrolyzing bPG, MRS with 1% 
skim milk was used as growth medium instead. 
In a similar way, LAB were grown in MRS overnight and then transferred into 
fresh MRS plus 1% skim milk growth medium. Lactobacilli were allowed to grow and 
subsequently 1 ml of LAB in MRS-1% skim milk was transferred into a 1.5 ml 
Eppendorf tube. Tubes were centrifuged at 10000 x g for 5 minutes to allow all the 
pellets to reach the bottom of the tube and obtain a clear supernatant. The supernatant 
was transferred into a new Eppendorf tube, and the pH was adjusted to 6-7 with 0.1-1 N 
NaOH. Subsequently, bPG (1mg/ml, 11.36μM) was added at 1:1 (v/v), and the solution 
was incubated at 37°C for 3 hours to test for extracellular enzymes presence and ability in 
bPG proteolysis.  
On the other hand, cell wall bound enzymes were purified following McGavin et 
al. (1993) procedures with modifications.  The pellets previously obtained were first 
  
36 
 
resuspended in 1 ml of phosphate buffered saline (PBS x1) using a rotor. Once the pellets 
were completely dissolved in PBS, samples were centrifuged at 10000 x g for 5 minutes. 
PBS was discarded and replaced by 1 ml 5M LiCl. Pellets were resuspended again using 
a rotor for approximately 1h. When no visible pellets were observed in the tube, the 
solution was centrifuged again for 30 seconds at 5000 rpm. At this point the supernatant 
obtained should contain the proteins that were previously bound to the surface of the 
microbes‟ cell wall. Dialysis was conducted by covering and sealing the top of the 
Eppendorf tube with a membrane (MWCO 3500 Da) and placing the tubes upside down 
in a water bath for a period of 3 hours. During this step, diffusion of LiCl outside the 
sample occurs while water molecules will travel in the opposite direction until a balance 
is reached. After the dialysis, samples‟ pH was adjusted to 6-7 with 0.1 HCl. Samples 
were concentrated using an Eppendorf vacufuge at 30°C until obtaining 100 µl solution. 
At this point 20 µl of the concentrated solution were added to 20 µl of bPG (1mg/ml, 
11.36 μM) and incubated for 3 hours at 37°C to test for ability of cell wall bound 
enzymes to hydrolyze bPG which was analyzed through SDS-PAGE and western blot. 
 
2.3.4.2  BACILLUS PROTEASES GENERATION ANALYSIS 
 
In a similar way as for Lactobacilli, ability of various strains of Bacilli in 
generating proteases capable of bPG hydrolysis was tested. A scheme of the experiment 
procedures can be observed in Figure 8.  
First, trypticase soy broth (TSB) was prepared (3% TSB in ddwater solution was 
autoclaved at 121°C for 15 minutes) and by using a loop, the various strains of Bacillus 
spores were inoculated and allowed to germinate and grow overnight at 37°C under 
aerobic conditions. Bacillus obtained from this step were then inoculated in UHT or TSB 
plus 5% UHT milk solution, to examine the effect of milk nutrients in triggering the 
expression of proteolytic enzymes. Proteoltytic activity was examined through skim milk 
agar plates as previously explained in section 2.3.4.1 for Lactobacilli. 
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Figure 8: Experimental design to determine Bacillus proteolytic enzymes generation in 
different growth media.   
 
2.3.4.2.1 Interaction of proteases generated from Bacillus strains with bovine 
plasminogen      
 
After analysis of the hydrolytic activity of the enzymes generated by the Bacillus 
strains tested, ability of the enzymes in cleaving bPG was determined. Bacilli were grown 
in fresh TSB-5% UHT milk overnight. Subsequently, 20 µl bPG (0.75 mg/ml, 8.52 μM) 
were added to 20 µl of each Bacillus solution and incubated at 37°C overnight to ensure 
that all enzymes have sufficient time to interact with bPG. Hydrolytic products were 
analyzed through SDS-PAGE and western blot. In order to better understand the enzymes 
affinity for the substrate and hydrolytic pattern of the reaction, the experiment was 
repeated under same conditions previously outlined, and samples were collected after 3, 
6, and 8 hours.  
Media effect on proteolytic enzymes production was also tested. Bacilli, after 
being grown in TSB, were inoculated in UHT alone overnight, and later tested for PG 
hydrolytic enzymes as for Bacillus grown in TSB-5%UHT. However, UHT samples had 
to be diluted 1:5 prior to incubation with bPG, to avoid total protein concentration in 
samples to be too high, and prevent poor results on SDS-PAGE.  
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  Bacillus trains that showed ability in generating higher amounts of fragments in 
the 38kDa region were used to generate large bands that were later analyzed for sequence 
analysis. After being grown in TSB-5%UHT media, the enzymes produced by the 
Bacillus strain ATCC 7050 (B. coagulans) showed highest angiostatin like fragments 
generation. ATCC 7050 was grown again under ideal conditions, and incubated with bPG 
at a final volume of 60 µl (3 times that previously used). This volume was added to a 
hand cast 15% tris HCl gel in which a well comb was modified to combine 3 wells to 
create a unique well capable of holding 60 µl sample volume. Electrophoresis as well as 
sequence analysis were conducted as described in sections 2.3.2.3.1 and 2.3.2.3.3.  
 
2.4 RESULTS AND DISCUSSION 
 
2.4.1 PART 1. Generation of angiostatin from bovine and human plasminogen 
hydrolysis by the action of Bacillus polymyxa protease 
 
2.4.1.1 Bovine plasminogen proteolytic fragments generated by Bacillus polymyxa 
protease 
 
Ability of BPP in generating 38 kDa fragments from bPG was evaluated. 
Additionally, enzyme activity as well as substrate concentration optimization was 
determined. SDS-PAGE analysis of samples of bPG and BPP incubated for 1 hour at 
37°C (Figure 9) shows that possible 38 kDa angiostatin like fragments were produced 
and that highest concentration of the peptides of interest is obtained when BPP is used at 
concentrations of 0.1, 0.125, 0.15 and 0.175 mg/ml with a substrate concentration of 1 
mg/ml. However, when the enzyme concentration is higher than 0.125mg/ml substrate 
depletion was observed, and BPP appears to be hydrolyzing some of the products of 
interest. This can be confirmed by the presence of darker bands in lower molecular 
weight regions (25-20 kDa). Based on these results 0.1 mg/ml seems a reasonable BPP 
concentration to work with for the rest of this study. 
 After identifying the ideal enzyme concentration, in order to evaluate the optimal 
substrate concentration, various amounts of bPG were reacted with a constant amount of 
BPP (0.1 mg/ml). As shown in Figure 10, for bPG higher than 0.5 mg/ml no significant 
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difference is observed for the products obtained or the amount of angiostatin like 
fragments that are generated. Based on these results, we can confirm that ideal substrate 
concentration is between 0.75-1 mg/ml and ideal enzyme concentration is 0.1 mg/ml.      
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 9: SDS-PAGE analysis of Bacillus polymyxa protease (BPP) and bovine 
plasminogen (bPG) ideal E:S ratio. Lane 1: molecular weight standard; lane 2: bPG 
control (0.25mg/ml); lane 3: BPP control (0.25 mg/ml); lane 4-10: bPG (1mg/ml) 
incubated with 0.025, 0.05, 0.075, 0.1, 0.125, 0.150 and 0.175mg/ml BPP in MTB for 1 
hour at 37°C. Bands in the 37 kDa area correspond to potential angiostatin (AS) 
fragments.        
  
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 10: SDS-PAGE analysis of Bacillus polymyxa protease (BPP) and bovine 
plasminogen (bPG) ideal E:S ratio. Lane 1: molecular weight standard; lane 2: bPG 
control (0.25mg/ml); lane 3: BPP control (0.25 mg/ml); lane 4-9: bPG at 0.125, 0.25, 0.5, 
0.75, 0.875 and 1mg/ml incubated with 0.1 mg/ml BPP in MTB for 1 hour at 37°C. 
Bands in the 37 kDa area correspond to potential angiostatin (AS) fragments.     
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 Subsequently, in order to determine the rate at which products of this reaction are 
formed (or substrate disappears) samples were taken at specific time intervals (Figure 
11); intensity variation of the bands over time was measured using a densitometer so as to 
study the kinetics of the reaction. From the SDS-PAGE gels obtained, it is possible to 
define the hydrolytic pattern produced from the interaction between BPP and bPG. 
Bacillus polymyxa protease will initially cleave bPG to generate PL (50 kDa), a second 
peptide with MW around 40 kDa and a fragment in the 35 kDa range after 5 and 10 
minutes incubation (Figure 11, lanes 4 and 5). Over time, it is possible to observe the 
band at 40 kDa becoming darker until incubation reaches approximately 30 minutes and 
then gradually fade away. On the other hand, the band observed at angiostatin‟s MW, 
around 37 kDa, keeps getting darker and thicker. It does not seem like BPP is 
hydrolyzing the potential angiostatin like fragment overtime. In summary, from these 
observations, we can presume that BPP will initially hydrolyze bPG in three parts. 
Subsequently, hydrolysis of fragments in the 50-40kDa area occurs to generate smaller 
peptides potentially belonging to angiostatin. Comparison of these results with those 
obtained in a similar experiment by Larsen et al. (2006), show the digests in this study 
slightly different hydrolytic patterns. In the present study the fragments obtained appear 
to be characterized by a lower molecular weight than those observed in the SDS-PAGE 
generated by Larsen et al. (2006). Possibly this can be explained by the fact that BPP 
purchased was not exactly the same in both studies, the enzyme used by Larsen et al. was 
discontinued and due to lack of information regarding this product it is not possible to 
fully explain the differences observed. 
 Analysis on the disappearance of bPG through the band density data observed in 
the graph in Figure 12, indicates that substrate hydrolysis occurs mostly during the first 
30 minutes, where the graph line is more sloping. After 60 minutes from the beginning of 
the reaction the curve seems to plateau indicating saturation (at this point the reaction rate 
will only depend on the speed and concentration of the enzyme). The same analysis was 
conducted for bPG at 0.5, 0.375, 0.25 mg/ml concentration, results are summarized on 
Table 5. From these results it is possible to conclude that higher difference in 
disappearing rate between 30 and 60 minutes occurs for higher substrate concentrations 
(0.625 and 0.5 mg/ml). While at lower bPG concentration this difference did not appear 
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to be significant since the enzyme is not saturated, and its speed will be only dependent 
on the substrate concentration. Analysis on appearance rate of product overtime, even 
though evident on the gels, could not be examined due to insufficient concentration 
required to overcome the background noise and for the densitometer to detect any 
significant difference in the amount of potential angiostatin fragments produced during 
the reaction. Moreover, a kinetic analysis through Lineweaver-Burk as well as Hanes-
Woolf Plot was conducted (results can be seen in Appendix A). The Km and Kcat 
obtained from this analysis however were incoherent with observations made from the 
SDS-PAGE gels obtained. Km for example, resulted to be very high (0.9) insinuating 
poor affinity between BPP and bPG, which as we can confirm from the images of the 
gels, it is not the case. A plausible explanation for obtaining these results may be that, in 
order to calculate the initial velocity change, band intensity variation over time was used 
instead of the actual bPG concentration. Due to the densitometer limitations in some 
cases to identify significant differences above or below specific thresholds, the data 
obtained through this method did not accurately reflect the facts.  These restraints are 
critical in the generation of an adequate Lineweaver-Burk due to its high sensitivity to 
data error, causing inaccuracy in the enzyme kinetic analysis particularly when low 
substrate concentrations are used (Storey Kenneth B. 2004). In this case, the inverse of 
very small substrate concentration is going to results in a larger number. In fact, as we 
can observe in Appendix A (Figure 63) for the point corresponding to the smallest 
concentration (0.25 mg/ml and for which the inverse equals 4), this point results to be 
isolated to the right of the graph. This data point will influence the resulting plotted line 
even more than the rest of the data points used (Bloomfield Victor 2009). For this reason, 
during the rest of this study the enzyme kinetics will be analyzed through the values of 
the slopes obtained from the density curves.                   
 From the western blot shown in Figure 13, it is clear that the fragments obtained 
in the molecular weight of 50, 37 and 25 kDa belong to bPG. The strong interaction 
between the primary anti-plasminogen antibody and the 37 kDa fragments indicate that 
the parameters used in this protocol are adequate for this study and that angiostatin like 
fragments are being produced.      
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Figure 11: SDS-PAGE analysis of angiostatin like fragments produced by bPG 
proteolysis by the action of BPP. Lane 1: MW standard; Lane 2: bPG control; Lane 3: 
BPP control; Lane 4 to 13: 0, 5, 10, 15, 20, 25, 30, 40, 50, 60 minutes bPG and BPP 
incubation. Fragments observed in the 37kDa area are potential angiostatin (AS) like 
fragments   
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Figure 12: bPG disappearance (0.625 mg/ml) over time by the action of BPP (0.1 mg/ml).   
Two slopes were measured, the first one was obtained by analyzing the data obtained after 
30 minutes of the reaction (-422.71), while the second slope was generated by considering 
all the points collected after one hour (-291.09).      
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Table 5: analysis of slopes obtained through bPG band density variation after 30 and 60 
minutes interaction with BPP  
bPG Concentration 
Slope After 30 
Minutes 
Slope After 60 
Minutes 
Initial 
Velocity 
(int/min-Vo) 
0.625 mg/ml -417.935 -291.09 442.13 
0.5 mg/ml -345.15 -291.39 426.8 
0.375 mg/ml -357.07 -341.13 341.73 
0.25 mg/ml -144.31 -167.93 242.25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 13: Western blot analysis of bPG fragments generated by digestion with BPP at 
various incubation times and E:S ratios. Reaction products were analyzed with an anti-
plasminogen antibody. Lane1: MW standard; Lane 2 to 5: 0.3125 mg/ml PG 0-40-50-60 
minutes incubation respectively; Lane 6 to 9: 0.375 mg/ml PG 0-30-40-50 minutes 
incubation respectively; Lane 10 to 13: 0.4375 mg/ml PG 0-30-40-50 minutes incubation 
respectively; Lane 14 to 17: 0.5 mg/ml PG 0-30-40-50 minutes incubation respectively. 
Immuno-reaction observed for bands in the 37kDa area confirm angiostatin (AS) like 
fragments being generated from this reaction  
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2.4.1.2 Temperature effect  
 
 A temperature effect was observed for enzyme-substrate interaction as well as 
substrate denaturation and consequent enzyme affinity and hydrolysis. From images 14 
and 17, it is possible to observe how temperatures 4, 37, 70 and 90°C, affected bPG-BPP 
interaction. Comparison between the reaction at 4°C and 37°C we can see that in a fridge 
like environment the reaction is much slower than that at room temperature. Lines 4 to 10 
show almost no difference in the amount of product generated or in bPG disappearance, 
contrarily to lines 12 to 18 were thicker and darker bands can be observed at 50, 37, 35 
and 25 kDa.  This observation is confirmed by analysis on the bands density variation 
over time (Figures 15 and 16), which indicate that bPG is hydrolyzed almost twice as fast 
at 37°C than at 4°C. Additionally, when this same analysis is conducted on bands 
observed at 37 and 34 kDa, no significant difference is recorded by the densitometer on 
the amount of product produced after 30 minutes at 4°C contrarily to when the reaction is 
carried out at 37°C, allowing us to conclude that in our study 37°C resulted to be the most 
favorable temperature for angiostatin generation. Under ideal temperature, evident 
product formation is observed and the rate at which peptides in the 37 and 34 kDa appear 
is almost the same.  
 At 70°C and 90°C, no activity seems to occur (Figure 17). Hydrolysis of bPG is 
not evident. These results are no surprise since, according to Matta and Punj (1998), 
dispase maintains 35% of its activity at 70°C for 10 minutes (Matta Hittu et al. 1998). 
Due to the reduced activity of the enzyme at this temperature and the short period of time 
that is being analyzed, it is not possible to observe any significant activity on the SDS-
PAGE obtained.    
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Figure 15: Rate at which BPP hydrolyzes bPG at 4°C and 37°C  
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Figure 14: SDS-PAGE analysis of temperature effect on BPP-bPG interaction. Lane 1: 
molecular weight standard; lane 2: bPG control (0.2 mg/ml); lane 3: BPP control 
(0.025mg/ml); lane 4-10: interaction at 4°C between bPG (0.75mg/ml) with BPP (0.1 
mg/ml) after 1, 5, 10, 15, 20, 25 and 30 minutes incubation; lane 11: molecular weight 
standard; lane 12-18: interaction at 37°C between bPG (0.75mg/ml) with BPP (0.1 
mg/ml) after 1, 5, 10, 15, 20, 25 and 30 minutes incubation 
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Figure 16: Rate at which bands in the 34 and 37 kDa are formed from bPG hydrolysis by 
the action of BPP at 4°C (A) and 37°C (B).  
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From the SDS-PAGE observed in Figure 18, we can observe how bPG 
denaturation affects BPP affinity for the substrate as well as the hydrolytic profile. Lanes 
from 2 to 6 represent optimal, 37°C, interaction between bPG and BPP. The rest of the 
gel, lanes 8 to 11, show the effect of heating bPG at 70°C (causing denaturation of the 
molecule) prior to incubation with BPP. Evident increased hydrolysis can be perceived 
particularly between 75 and 50 kDa molecular weight range. These results concord with 
the observations previously made by Burbrink and Hayes (2006), in which they 
determined that by denaturating PG, uPA had easier access to the internal bPG structure 
and consequent higher activation of the molecule was observed since higher 
concentration of PL in the sample. Moreover, it seems that higher concentration of the 
bands of interest in the 37 kDa is also observed (comparison between lane 6 and 11). 
Further confirmation of these observations can be made from the band density analysis 
graphs observed in Figure 19 and 20. From this analysis it is possible to ratify bPG being 
hydrolyzed at higher rate when in a denatured state. In fact, according to the slope of the 
curves obtained, it seems that BPP hydrolyzes denatured bPG more than twice as fast as 
non denatured bPG. However, the product formation rate for bands in the 37-34 kDa area 
Figure 17: SDS-PAGE analysis of temperature effect on BPP-bPG interaction. Lane 1: 
molecular weight standard; lane 2: bPG control (0.2 mg/ml); lane 3: BPP control 
(0.025mg/ml); lane 4-10: interaction at 70°C between bPG (0.75mg/ml) with BPP (0.1 
mg/ml) after 1, 2, 3, 4, 5, 6, 7 minutes incubation; lane 11: molecular weight standard; 
lane 12-18: interaction at 90°C between bPG (0.75mg/ml) with BPP (0.1 mg/ml) after 1, 
2, 3, 4, 5, 6, 7 minutes incubation 
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do not seem to significantly differ from that observed in previous analysis at 37°C (Figure 
16 B). Direct analysis on product formation for non denatured bPG from the gel observed 
in Figure 18 was not possible due to insufficient product generation for the densitometer 
to detect a significant difference in the concentration of the bands overtime. In 
conclusion, although by visually looking at the gel and comparing lanes 6 and 11 it seems 
that angiostatin like fragments are produced at higher concentration by the action of BPP 
when bPG is denatured, it is not possible to confirm such observation from the numbers 
obtained through density analysis since the amount of product generated is not enough to 
enable direct comparison in the present gel image.  
Subsequently, effect of bPG hydrolysis, folded and unfolded, in a milk system 
and consequent BPP activity was also determined. Referring to Figure 21, we can 
observe differences between hydrolysis of folded bPG and denatured bPG in milk. 
Contrarily to the observations previously made when the reaction was conducted in a 
buffer system, the same hydrolytic pattern is observed between native and denatured bPG 
by the action of BPP. Nevertheless, the reaction for denatured bPG seems to produce 
higher amount of fragments in the 50 kDa molecular weight range as well as higher bPG 
disappearance rate compared to the results observed when bPG did not undergo heating 
prior to incubation with dispase. According to the bPG disappearance rate analysis 
(Figure 22), denatured bPG gets hydrolyzed faster than native bPG, similarly to what 
previously seen in a buffer system. However, this difference is not as pronounced as the 
one seen in a buffer system, these rates differ by 1.52 times when analyzed in milk 
compared to 2.2 times in buffer. These observations can be explained by the fact that due 
to the presence of additional proteins in milk, BPP priority is not only bPG hydrolysis but 
also interaction with other high affinity peptides. These results are in accordance with 
findings made by Lu et al. (2009) for which analysis of various heat treatments on PG in 
milk resulted in higher PG activity (due to increased PL) when the zymogen was heated 
at 70°C (Platanias Leonidas C. 2009). On the other hand, through density analysis, 
angiostatin like fragments generation seems to be slightly higher (1.2 times) in milk for 
denatured bPG than in buffer. Various factors could explain such phenomenon. For 
example, presence of specific activators or some other molecules may function as 
angiostatin generation promoters; if this was true we would also observe higher 
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generation of angiostatin for native bPG in milk, however detection limitations did not 
allow us to investigate such hypothesis further. Moreover, according to observations 
previously made for the hydrolytic pattern observed in Figure 11, if true that BPP can 
generate angiostatin from a fragment in the 50 kDa range (believed to be PL), then the 
higher concentration of this fragment observed under such conditions could explain 
consequent higher angiostatin generation.       
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: SDS-PAGE analysis of denaturation effect on bPG hydrolysis by the action of 
BPP at 37°C. Lane 1: molecular weight standard; lane 2-6: native bPG (0.75mg/ml) 
incubated with BPP (0.1mg/ml) at 37°C for 1, 5, 10, 20 and 30 minutes incubation; lane 
7-11: denatured bPG (heated at 70°C) incubated with BPP at 37°C for 1, 5, 10, 20 and 30 
minutes.     
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Figure 19: Disappearance rate comparison between denatured and non denatured bPG by 
the action of BPP. Disappearance of native bPG resulted in a slope of -265.26 while 
denatured bPG showed -571.66 disappearance rate.    
 
 
 
 
Figure 20: Production rate of 35 and 37 molecular weight peptides generated through 
denatured bPG hydrolysis by the action of BPP  
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Figure 22: denatured versus non denatured bPG proteolysis by the action of BPP when in 
a milk system. The rate of the reaction resulted in a slope of -208.63 when bPG is in its 
native form, while -316.79 for bPG in its denatured form.  
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Figure 21: SDS-PAGE analysis of fragments generated by the action of BPP with folded 
and denatured bPG in a milk system. Lane 1: molecular weight standard; lane 2-6: bPG 
in milk incubated with BPP at 37°C for 1, 5, 10, 20 and 30 minutes; lane 7-11: denatured 
bPG in milk incubated with BPP at 37°C for 1, 5, 10, 20 and 30 minutes 
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Figure 23: 35 and 37 kDa fragments generation from denatured bPG in milk by the action 
of BPP 
 
2.4.1.3 Sequence analysis of fragments of interest 
 
Sequence analysis of the fragments generated by BPP with molecular weight of 
50 kDa, 37 kDa and 35 kDa (observed in Figure 11) confirmed the fragments to belong to 
plasmin, kringles 1 through 4 of bovine plasminogen and mini-plasminogen respectively 
(Appendix B). For more accurate interpretation of the results obtained, only actual minus 
calculated peptide mass data in the range of ± 200 ppm were considered.    
 
2.4.1.4 Bacillus polymyxa protease ability in generating human angiostatin  
 
  Ability of BPP in generating angiostatin from human PG was confirmed. 
Additionally, from the results obtained from this study it was possible to notice the 
evident higher affinity of BPP for human PG than for the bovine source of this molecule, 
since 10 fold less concentrated enzyme was necessary to generate angiostatin and other 
fragments. In Figures 24 and 25, products generated over time by BPP at two 
concentration levels can be observed. Figure 25, when BPP concentration is 0.025 mg/ml, 
shows that after less than 5 minutes incubation the reaction is terminated. Interestingly, 
even 25 minutes after products being generated, hydrolysis of the fragments of interest 
does not occur. From the reaction observed in Figure 25, in which a lower concentration 
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of BPP is used (0.01 mg/ml; 10 fold less concentrated than that used for bPG), similar 
results are observed. BPP hydrolyzed hPG to generate PL (50kDa), a thick band between 
50 and 37 kDa (which could represent angiostatin K1-4 or K1-3 or a combination of 
other kringles) and a fragment which molecular weight is lower than that of angiostatin. 
Interestingly, when the concentration of BPP is increased, a band in the 37 kDa appears, 
indicating that angiostatin in Figure 25 is being produced but at a very slow rate and 
almost not visible in the gel. Kinetics on BPP hydrolysis of hPG was not conducted since 
as it is possible to confirm from the gels obtained, at low concentration of BPP the 
reaction is very slow, particularly in generating the fragment of interest, while at higher 
concentration the angiostatin like fragment is obtained after less than 5 minutes 
incubation with the substrate, making it difficult to adjust concentration-time 
paramenters. However, the major observation and objective of this experiment was 
reached, and it is possible to confirm with great evidence that BPP has higher affinity for 
hPG than for bPG, and it will produce higher amounts of angiostatin like fragments from 
the human version of the molecule than bPG.       
 Western blot analysis of the SDS-PAGE obtained for the reaction between BPP 
(0.01mg/ml) and hPG (1mg/ml) in Figure 25 can be observed in Figure 26. Polyclonal 
anti-human angiostatin antibody used in this study, recognizes angiostatin K1-4 and part 
of K5 according to the manufacturer. From the results, bands located between 50 and 37 
kDa show strong immunoreaction with the antibody. We can assume from this interaction 
that angiostatin K1-4 is being produced and its molecular weight may be higher than 
38kDa. Interestingly from the literature many variations on angiostatin‟s MW from 35 to 
45 kDa (Cao Yihai et al. 1996; Morikawa Wataru et al. 2000; Migita Toshiro et al. 2001) 
are found, making it difficut to guess and exactly determine which kringles are being  
generated without sequence analysis data.  Additionally,  lower molecular weight 
fragments observed could represent combinations of some of the kringles. According to 
Cao et al. (1996) native angiostatin K1-3 had a MW of approximately 35 kDa, but 
according to a study conducted by Migita et al. (2001) this molecular weight represented 
native mini-plasminogen (K5 plus the light chain); in order to better understand and to 
confirm what products are being obtained sequence analysis is necessary.     
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Figure 24: SDS-PAGE visualization of the fragments generated by the action of BPP 
(0.025 mg/ml) hydrolysis of human PG (1mg/ml). Lane 1: molecular weight standard; 
lane 2: hPG control (0.125 mg/ml); lane 3: BPP control (0.025 mg/ml); lane 4-8: hPG 
incubated with BPP for 0, 5, 10, 15, and 20 minutes incubation at 37°C.   
Figure 25: SDS-PAGE visualization of the fragments generated by the action of BPP 
(0.01 mg/ml) hydrolysis of human PG (1mg/ml). Lane 1: molecular weight standard; 
lane 2: hPG control (0.125 mg/ml); lane 3: BPP control (0.025 mg/ml); lane 4-9: hPG 
incubated with BPP for 0, 1, 11, 21, 31 and 41 minutes incubation at 37°C.   
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2.4.2 PART 2. Generation of angiostatin from bovine and human plasminogen 
hydrolysis by the action of elastase 
 
From previous studies, it is known that elastase is capable of producing 
angiostatin K1-4, K1-3 and K4 alone from human PG (Cao Yihai et al. 1996). From this 
study we were able to determine that elastase can generate angiostatin like fragments 
from bPG as well. From the SDS-PAGE shown in Figure 27, a clear band in the 38kDa 
can be identified from the products obtained from the interaction between elastase and 
bPG. Interestingly, contrarily to BPP, elastase does not produce secondary products (i.e. 
PL), only angiostatin and a lower molecular weight band (possibly K1-3 or mini-
plasminogen) are observed. The western-blot (Figure 30) also confirms the bands 
obtained to belong to internal region of bPG. Additionally, from the band density 
analysis, the slope of bPG disappearance confirms the reaction to be very slow compared 
to BPP since in this case the reaction is analyzed over a period of 8 hours instead of 1 
hour. This significant difference in incubation time does not allow direct comparison 
between the two enzymes in terms of kinetics. In order to enable comparison on the 
amount of product produced, intensity values could be used instead. Higher intensity is 
observed for bands in the 37 and 34 kDa area generated through hydrolysis action from 
elastase. The intensity of these bands is almost twice as stronger as the same bands when 
Figure 26: Western-blot visualization of internal human PG fragments generated by the 
action of BPP (0.01 mg/ml), identified with polyclonal anti-human angiostatin. Lane 1: 
molecular weight standard; lane 2: hPG control (0.125 mg/ml); lane 3: BPP control 
(0.025 mg/ml); lane 4-9: hPG incubated with BPP for 0, 1, 11, 21, 31 and 41 minutes at 
37°C.   
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generated by BPP (comparison between Figure 29 and 16 B), indicating ability of 
elastase in producing higher amounts of angiostatin from the same PG concentration.        
From the hPG interaction with elastase shown in Figure 31, we notice that under 
the same conditions (E:S ratio, time and temperature) used for bPG, elastase shows 
higher affinity for bPG than for hPG, since hydrolysis of hPG is slower than that 
observed for bPG. Additionally, a different hydrolytic pattern between the two substrates 
is also observed. Higher molecular weight bands are generated from hPG hydrolysis. 
Moreover, from the western blot obtained two clear bands can be recognized possibly as 
human angiostatin K1-4 and K1-3 as seen in the experiment conducted by Cao et al. 
(1996). Lower MW bands able to immuno-react with the anti-human angiostatin antibody 
are also observed. Two main factors differ between our experiment and that conducted by 
Cao et al. (1996): the elastase source and the E:S ratio. The elastase used in the present 
study has been purified from human leukocytes while Cao et al. used porcine elastase. 
Additionally the E:S ratio used in our study was 1:100, while Cao et al. used a 1:133 
ratio. Perhaps these differences may explain some of the dissimilarities observed between 
the two studies.  
 
    
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: SDS-PAGE analysis of the fragments obtained through bPG hydrolysis by 
the action of elastase. Lane 1-5: elastase (0.01 mg/ml) incubated with bPG (1mg/ml) for 
1, 2, 4, 6 and 8 hours incubation at 37°C; lane 6: molecular weight standard. Bands in 
the 37 kDa correspond to potential angiostatin (AS) fragments   
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Figure 28: bPG disappearance by the action of elastase overtime 
 
 
 
 
 
Figure 29: generation rate of fragments obtained through bPG hydrolysis by the action of 
elastase 
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Figure 30: SDS-PAGE analysis of proteolytic fragments generated through bovine PG 
hydrolysis by the action of elastase (E) and identified with a polyclonal anti-bovine 
plasminogen antibody. Lane 1: molecular weight standard; lane 2: bPG control (0.25 
mg/ml); lane 3: elastase control (0.025mg/ml); lane 4-8: bPG (1mg/ml) interaction with 
elastase (0.01 mg/ml) after 1, 2, 4, 6 and 8 hours incubation at 37°C. Bands in the 37kDa 
area correspond to potential angiostatin AS fragments.   
Figure 31: SDS-PAGE analysis of hydrolytic products obtained from human PG 
hydrolysis by the action of elastase. Lane 1: molecular weight standard; lane 2: hPG 
control (0.125mg/ml); lane 3-8: hPG (1mg/ml) incubated with elastase for 30 minutes, 
1, 2, 4, 6 and 8 hours at 37°C.   
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2.4.3 PART 3. Generation of angiostatin from bovine plasminogen hydrolysis by the 
action of Bacillus and Lactobacillus originated proteases 
 
2.4.3.1 LACTOBACILLUS 
 
Generation of proteolytic enzymes by Lactobacillus grown in UHT was 
quantified (Table 6) based on observations from skim milk agar plates in Figure 33. 
Zones of clearance indicate casein break down by proteases generated by the action of 
Lactobacilli. Different results can be observed by different strains of LAB. L. reuteri 
23272 and L. johnsonii 11088 showed higher caseinolytic activity compared to the other 
strains which showed low to no activity. Effects of other growth media, MRS-5% UHT, 
on the generation of hydrolytic enzymes was also determined, however results indicated 
almost no caseinolytic activity (for hydrolytic activity of lactobacillus grown in MRS- 
5% UHT refer to Appendix C).  
Determination of bPG proteolytic enzyme generation was also analyzed, but from 
Figures 34 and 35 we can observe that neither the enzymes released in the supernatant 
Figure 32: western blot identification of internal human PG fragments generated by the 
action of elastase through anti-human angiostatin polyclonal antibody. Lane 1: 
molecular weight standard; lane 2: hPG control (0.125 mg/ml); lane 3-8: elastase 
(0.1mg/ml) interaction with hPG (1mg/ml) after 30 minutes, 1, 2, 4, 6 and 8 hours 
incubation.  
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nor those bound to the cell wall surface showed capability in hydrolyzing PG. In Figure 
34, for L. helveticus MR 220 a band is observed at 50 kDa. Further research through 
western blot analysis (results not shown), indicated this fragment not to belong to bPG 
since no immunoreactions with polyclonal anti-bovine plasminogen occurred.   
 
 
 
 
Figure 33: Skim milk agar plates hydrolytic activity analysis of Lactobacillus grown in 
UHT. Zones of clearance indicate production of caseinolytic enzymes.   
 
 
 
 
 
 
 
 
23272 25302 
L.C.10 NCFM 
T-1 MR220 
Control L.C.661 
23272 11088 
25302 11284 
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Table 6: measures of zone of clearance (in mm) produced by the action of Lactobacillus 
originated enzymes when placed in casein agar plates for 24 hours   
*zone of clearance was measured by taking the average of the vertical and horizontal 
diameters (in mm) of the halo observed in the skim milk agar plates Figure 33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lactobacillus Zone of clearance diameter (mm)* 
L.C. 10 17 
NCFM 13 
T-1 0 
MR 220 22 
23272 19 
11088 20 
25302 0 
11284 9 
L.C.661 0 
Control 0 
Figure 34: SDS-PAGE analysis of enzymes released by Lactobacilli in the supernatant 
to hydrolyze bPG. Lane 1: molecular weight standard; lane 2: bPG control 
(0.125mg/ml); lane 3-11: bPG (1mg/ml) interaction with the supernatant produced from 
Lactobacillus NCFM, T-1, MR220, 85302, 11088, L.C. 10, 23272, 661, and 11284 after 
3 hours incubation at 37°C.    
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2.4.3.2 BACILLUS 
 
 Contrary to Lactobacillus, most of the Bacillus strains tested showed pronounced 
hydrolytic activity. In fact from Figure 36 we can see defined zones of clearance between 
various Bacillus strains and also differences between strains grown in UHT and TSB-5% 
UHT. Similar hydrolytic activity is observed between the two media tested. Enzymes 
generation by Bacillus after 12 or 24 hours growth in TSB alone was also analyzed 
(Appendix D). Interestingly, enzymes were more active when generated after 12 hours 
growth than 1 day after inoculation. Nutrient depletion after 24 hours growth may explain 
the reduced enzyme generation.  Ability of the strains analyzed in hydrolyzing casein are 
in agreement with the observations made by Gordon et al.(1973) which classified 
Bacillus strains characteristics, including casein hydrolysis, and observed that the 
majority of the strains analyzed were positive for this trait (Turnbull Peter C. B. 1996).   
These proteases resulted positive also in their ability in bPG hydrolysis (Figure 
37). SDS-PAGE analysis of the products obtained from the reaction between Bacilli 
derived enzymes and bPG shows that all the Bacilli produced proteases capable of 
interacting with bPG. However differences in substrate affinity and kinetics in cleaving 
Figure 35: SDS-PAGE analysis of isolated cell wall associated enzymes ability in 
hydrolyzind bPG. Lane 1: molecular weight standard; lane 2: bPG control (0.125 
mg/ml); lane 3-11: interaction between bPG (1mg/ml) and cell wall associated enzymes 
isolated from Lactobacillus 661, NCFM, 23272, 11088, 11284, L.C. 10, T-1 and 
MR220.    
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PG is observed between the various strains of Bacilli analyzed. Looking at the substrate 
disappearance in Figure 37 and 38 we can separate the proteases in three categories: high 
(B. megaterium ATCC 14581, B. subtilis 23857, B. brevis 8186, B. stearothermophilus 
12980, B. licheniformis 12759, B. cereus 14579, B. amyloliquefaciens 23842 and B. 
licheniformis 14580) medium (B. stearothermophilus DIFCO and B. coagulans ATCC 
7050) and low substrate affinity (B. pumilus ATCC 72, B. subtilis 23059, B. circulans 
4513 and B. polymyxa 301).   
Experiment conducted by growing Bacillus in UHT milk showed generation of 
enzymes with similar hydrolytic pattern (Figure 39). Some variations however are 
observed that may be explained by higher protein content in the sample other than bPG. 
Enzymes may have higher affinity for proteins other than bPG, explaining why bPG is 
not as hydrolyzed as when Bacilli are grown in TSB with 5% UHT. However, it is 
interesting to notice that most of the Bacillus that were previously categorized as high 
bPG affinity enzymes producers when grown in TSB with 5% UHT, will still be 
recognized as such, as well as the medium and low categories. The most evident 
difference among these two gels (Figure 37 and 39) is in the hydrolysis of a fragment in 
the 50 kDa molecular weight range (which we can assume to be PL). Bacillus grown in 
TSB with 5% UHT show higher disappearance of this 50 kDa fragment than when grown 
in UHT only. Additionally, bacillus for which this fragment is not produced (when 
compared to their activity in TSB-5% UHT) showed little to no bPG hydrolysis. Again 
this observation may be explained by presence of proteins other that bPG for which 
bacillus enzymes show high affinity.     
From Figure 37, it is possible to notice that B. coagulans ATCC 7050 resulted in 
higher angiostatin like fragments generation that also showed higher immunoreaction in 
western-blotting (Figure 40). This strain was used to produce big and large bands (Figure 
41) that were later sent for sequence analysis, which results are shown on Appendix E. 
The results obtained from sequence analysis resulted somewhat confusing, since chances 
of K1-4 being produced was higher for peptides obtained in the lower molecular weight 
range (25-20 kDa) than for bands obtained at molecular weight known to correspond to 
angiostatin. Perhaps, various kringles combinations with similar molecular weight are 
being produced by ATCC 7050 enzymes. If this is the case, we will not be able to 
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distinguish and identify through sequence analysis the various fragments being obtained. 
Other procedures should be used to better examine what fragments are being produced.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36: Skim milk agar plates for Bacillus hydrolytic activity analysis after growth in 
TSB+5% UHT or UHT for 12h. 
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Table 7: measurements of zone of clearance obtained by the action of Bacillus generated 
enzymes when incubated in casein skim milk agar plates  
Bacillus Zone of clearance after 
growth in TSB -5%UHT 
(mm) 
Zone of clearance after 
growth in UHT (mm) 
Control 0 0 
4513 17 20 
23059 18 25 
8186 26 26 
301 20 20 
7050 ≈21 ≈20 
14579 ≈30 >40 
23857 24 25 
14581 25 25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37: SDS-PAGE analysis of bPG hydrolysis by the action of Bacillus derived 
proteases when grown in TSB-5%UHT. Lane 1: molecular weight standard; lane 2: bPG 
control (0.2 mg/ml); lane 3: media control (TSB-5% UHT); lane 4-17: bPG interaction 
with derived proteases from Bacillus ATCC14581 (lane 4), 23857 (lane5), 8186 (lane 6), 
72 (lane 7), DIFCO (lane 8), 12980 (lane 9), 12759 (lane 10), 7050 (lane 11), 14579 (lane 
12), 23059 (lane 13), 4513 (lane 14), 301 (lane 15), 23842 (lane 16) and 14580 (lane 17); 
lane 18: bPG in TSB-5%UHT control. Fragments in the 37 kDa represent potential 
angiostatin (AS) fragments.      
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Figure 38: Column chart indicating differences between various Bacilli tested in 
generating enzymes capable of hydrolyzing bPG. The highest the column the LOWEST 
the amount of enzymes produced since each column indicates the amount of bPG in 
solution at the end of the reaction (based on Figure 37). Vice versa, the lower the column 
the HIGHER the ability of the bacillus in generating bPG hydrolytic enzymes. In order 
from 1 to 14 the columns represent bPG hydrolyzed by Bacillus ATCC14581 (column 1), 
23857 (column 2), 8186 (column 3), 72 (column 4), DIFCO (column 5), 12980 (column 
6), 12759 (column 7), 7050 (column 8), 14579 (column 9), 23059 (column 10), 4513 
(column 11), 301 (column 12), 23842 (column 13) and 14580 (column 14) respectively; 
column 15 represents bPG in TSB-5%UHT control.     
 
 
 
Figure 39: SDS-PAGE analysis of bPG hydrolysis by the action of Bacillus derived 
proteases when grown in UHT. Lane 1: molecular weight standard; lane 2: media control 
(UHT 1:5); lane 3: bPG in UHT 1:5 control; lane 4-17: bPG interaction with derived 
proteases from Bacillus ATCC14581 (lane 4), 23857 (lane 5), 8186 (lane 6), 72 (lane 7), 
DIFCO (lane 8), 12980 (lane 9), 12759 (lane 10), 7050 (lane 11), 14579 (lane 12), 23059 
(lane 13), 4513 (lane 14), 301 (lane 15), 23842 (lane 16) and 14580 (lane 17) 
respectively.     
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Figure 40: Western blot identification of internal bPG fragments generated by the action 
of Bacillus produced proteases when grown in TSB-5%UHT, by using a polyclonal anti-
bovine plasminogen antibody. Lane 1: molecular weight standard; lane 2: bPG control 
(0.2 mg/ml); lane 3: media control (TSB-5% UHT); lane 4-17: bPG interaction with 
derived proteases from Bacillus ATCC14581, 23857, 8186, 72, DIFCO, 12980, 12759, 
7050, 14579, 23059, 4513, 301, 23842 and 14580 respectively; lane 18: bPG in TSB-
5%UHT control.   
   
 
 
 
 
 
 
 
 
Figure 41: SDS-PAGE produced for sequence analysis of fragments generated through 
bPG hydrolysis by the action of Bacillus ATCC 7050 grown in TSB-5% UHT. Lane 1: 
molecular weight standard; lane 2: bPG control (0.125 mg/ml); lane 3: media control 
(TSB-5%UHT); lane 4: media control (UHT 1:5); lane 5: bPG in TSB-5%UHT control 
incubated for 18 hours; lane 6: bPG in UHT control incubated for 18 hours; lane 7: bPG 
incubated with enzymes generated by bacillus ATCC 7050 after growth in TSB-5%UHT; 
lane 8: bPG incubated with enzymes generated by bacillus ATCC 7050 after growth in 
UHT.  
 1       2     3      4    5      6     7     8     9    10    11  12  13   14   15   16   17    18 
 
250 
150 
100 
75 
 
50 
 
37 
 
 
25 
 
20 
1       2       3      4      5      6                       
ATCC 7050 in 
TSB5%UHT + bPG 
ATCC 7050 in UHT + 
bPG 
250 
150 
100 
75 
 
50 
37 
 
 
25 
 
20 
 
15 
  
68 
 
2.5 CONCLUSIONS 
 
Results revealed the ability of various enzymes to generate angiostatin like 
fragments from bPG in a similar way to angiostatin generation from hPG. Of all the 
enzymes analyzed BPP and elastase showed higher affinity for bPG and consequent 
angiostatin generation. B. polymyxa protease however, showed higher affinity for hPG 
since compared to bPG 10 fold less concentrated enzyme as well as less incubation time 
were necessary to obtain angiostatin like fragments. On the other hand, elastase was 
preferred to generate angiostatin from bovine than human PG since angiostatin was the 
main product of this hydrolysis, and little secondary products were generated compared 
to hPG. Subsequently, from the examination of Bacillus and Lactobacillus ability in 
generating proteases during growth, we discovered ability of all Bacillus to produce 
proteases capable of hydrolyzing bPG and some even generating angiostatin like 
fragments, while none of the Lactobacilli analyzed generated enzymes (released or cell 
wall associated) displaying such characteristic. At this point, it remains to investigate if 
these bovine angiostatin like fragments generated have anti-cancer activity and how 
similar it is to that known for human angiostatin. The next chapters will investigate the 
anticancer activity of bovine angiostatin, and also the ability of this peptide to survive 
digestive enzymes proteolysis.  
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III. ANTI-CANCER ACTIVITY ANALYSIS OF BOVINE ANGIOSTATIN 
3.1 ABSTRACT 
 
 Ability of bovine angiostatin in inhibiting malignant melanoma and colon 
cancerous cells growth was analyzed. This analysis was conducted on in vitro models 
using SW480 human colon cancer cells lines and reconstructed human malignant 
melanoma (A375) skin model. For the colon cancer analysis, bovine angiostatin as well 
as bovine plasminogen (bPG) and the enzyme used to generate angiostatin from bPG 
(Bacillus polymyxa protease, BPP), were used and anticancer activities analyzed and 
compared. Results from this investigation showed ability of bovine angiostatin in 
inhibiting colon cancer cells growth by 100% when administered at 3 µg/ml. Moreover, 
bPG as well as BPP controls showed some anticancer effect but never reached complete 
inhibition as the angiostatin treatment. From the second study conducted on melanoma, 
additionally to bovine angiostatin, bPG and BPP, human angiostatin and human 
plasminogen (hPG) were also used as controls to allow direct comparison with anticancer 
activity of that already known for human angiostatin. Findings from this investigation 
indicate ability of both human and bovine angiostatin as well as human and bovine 
plasminogen in notably inhibiting the spread of malignant cells when compared to BPP 
and a negative control. These preliminary results confirm potential similarity between 
human and bovine angiostatin and their ability in inhibiting cancerous cells. 
 
3.2 INTRODUCTION 
 
Angiostatin is recognized as one of the most potent antiangiogenic molecules 
known to date (Cao Renhai et al. 1999; Wahl Miriam L. et al. 2004). Interestingly 
angiostatin is not only known to inhibit the development of blood vessels involved in 
“feeding” a tumor through supply of nutrients and oxygen, but also in causing direct 
malignant cells necrosis by interacting and inhibiting ATP-synthase, a surface enzyme 
which function is to maintain a normal internal pH; failure of this enzyme by the action 
of angiostatin will impede protons inside the cell to escape into the extracellular 
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environment causing the internal pH to decrease compromising the cells survival (Wahl 
Miriam L.  et al. 2005; Figg William D. et al. 2008; Mowery Yvonne M. et al. 2009).  
Angiostatin is produced through hydrolysis of fibrinolytic zymogen PG (Wahl 
Miriam L. et al. 2004). Many are the enzymes that have shown ability in angiostatin 
generation. Additionally, depending on where plasminogen is hydrolyzed many 
angiostatin variants are created each showing a specific anti-cancer activity (either ECs 
proliferation or migration inhibition or direct cancerous cells growth restriction) (Cao 
Yihai et al. 1996; Ji Weidong-richard et al. 1998; Cao Renhai et al. 1999; MacDonald 
Nicholas J. et al. 1999; Geiger J. H. et al. 2004). 
Interestingly many animals show fibrinolytic systems similar to that of humans, 
and many of the plasmin system components (from activators to inhibitors) get 
transferred into milk during milk production (Korycha-Dahl M. et al. 1983; Bastian Eric 
D. et al. 1996; Ismail B. et al. 2010). It is known that PG from bovine origin shares 78% 
homology with hPG. Moreover, average similarity among kringles, the region 
corresponding to angiostatin, is of 83% (Schaller J. et al. 1985). Despite the resemblance 
between human and bovine plasminogen, and the fact that bovine milk is highly 
consumed in the U.S. and other countries, no in depth research on the potential of bPG in 
generating angiostatin like fragments with anticancer activity has been studied to date.  
From previous studies conducted in our laboratory we confirmed ability of 
angiostatin to be produced from bPG by the action of a variety of enzymes. The obtained 
fragments seem to be structurally comparable to that known for human angiostatin. From 
this study anticancer activity of bovine angiostatin was analyzed through malignant colon 
and melanoma cells in vitro models. Results demonstrated evident delay in the 
proliferation of cancerous cells compared to controls when treated both with human and 
bovine angiostatin and plasminogen. In conclusion, the preliminary results obtained from 
this study open a new area of research for future development of novel dairy products 
capable of cancer prevention.  
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3.3 EXPERIMENTAL PROCEDURES  
 
3.3.1 REAGENTS AND SOURCES  
 
Bovine plasminogen (product # 416), human glu-plasminogen (product # 412) were 
purchased from American Diagnostica (Greenwich, CT). Dispase I (BPP) (product # 
D4818) was purchased from Sigma-Aldrich (St. Louis, MO).  
 
3.3.2 Inhibition of cancerous cells growth by the action of angiostatin 
In order to determine possible anti-cancer activity of angiostatin produced from 
bPG hydrolysis by the action of B. polymyxa protease, inhibition of malignant colon 
cancer cells as well as melanoma growth was analyzed. Controls such as human 
angiostatin and plasminogen alone (both from human and bovine sources) were used.  
 
3.3.2.1  Preparation of angiostatin for colon cancerous cells inhibition analysis  
 
Three samples, one treatment and two controls, were prepared and tested on 
SW480 human colon cancer cells which was conducted at Teagasc, the Agriculture and 
Food Development Authority, in Oak Park, Carlow, Ireland.   
Solution of bPG alone at a final concentration of 0.375mg/ml (4.26μM) and BPP 
containing a total of 0.075mg/ml (2.08μM) protein were used as controls in 2% NFDM. 
The treatment was prepared by reacting 1:1 (v/v) ratio bPG (1mg/ml, 11.36μM) and BPP 
(0.1mg/ml, 2.78μM) at 37°C for 1 hour. Subsequently, 2% NFDM was added to the total 
bPG-BPP volume to have a final concentration of the substrate and the enzyme similar to 
that of the controls. Samples were boiled for 5minutes to stop the reaction and stored at -
15°C until analysis.  
 
3.3.2.2 Angiostatin for melanoma inhibition activity samples preparation  
 
Samples tested for melanoma growth inhibition, included hPG as a control and 
human angiostatin generated from BPP. Human PG and bPG controls were both prepared 
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to a final concentration of 0.164 mg/ml (1.86μM) in ddwater. Human angiostatin was 
prepared by incubating hPG (1mg/ml, 11.36μM) with BPP (0.025 mg/ml, 0.69μM) at 1:1 
(v/v) ratio for 30 minutes at 37°C; ddwater was then added to dilute samples to a final 
concentration of 0.164 mg/ml (1.86μM) for hPG and 0.0041 mg/ml (113.89nM) for BPP 
(these dilutions were chosen since not possible to directly quantify the amount of 
plasminogen present at the end of the reaction, we assumed all fragments belonging to 
plasminogen after being hydrolyzed would equal the amount of plasminogen in the 
control and allow comparison of the results obtained). Bovine angiostatin was prepared 
by incubating bPG (1mg/ml, 11.36μM) with BPP (0.1mg/ml, 2.78μM) for 1 hour at 37°C 
at 1:1 ratio. Similarly to human angiostatin, samples were diluted with ddwater in order 
to obtain a total final concentration of 0.164 mg/ml (1.86μM) for bPG and 0.0164mg/ml 
(455.56 nM) of BPP. Samples were diluted in order to obtain similar protein content in 
each sample and allow comparison in anticancer activity. BPP control was prepared by 
using the highest concentration of the enzyme used to prepare bovine angiostatin (0.0164 
mg/ml, 455.56 nM).  
 The experiment on melanoma cells was conducted at the department of 
Biomedical Engineering at California Polytechnic State University, were melanoma skin 
model tissues (MatTek, Ashland, MA) were incubated with their respective sample 
(which were further diluted in 5ml buffer prior to melanoma specimen treatment) every 
other day for a two-week period of time. If we take into account also this final dilution, 
the real final concentration at which bPG and hPG were analyzed is 0.0164 mg/ml 
(186.4nM) (approximately 9 times more concentrated than the average amount of bPG in 
milk (1.8µg/ml, 20.45 nM) (Ismail B. et al. 2010)).   
 
3.4 RESULTS AND DISCUSSION  
 
3.4.1 COLON CANCER INHIBITION  
 
According to the graph in Figure 42, we can observe that angiostatin treatment 
caused 100% growth inhibition of cancerous cells when administered at a concentration 
of approximately 3 µg/ml (concentration of PG in milk is between 0.8-2.8 µg/ml). On the 
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other hand, controls, which are also present in the treatment since not pure but at a much 
lower concentration, showed also some cytotoxicity however not as high as inhibition 
caused by angiostatin.  
 
Figure 42: graph illustrating ability of various samples tested for their ability in inhibiting 
colon cancer cells growth. Samples tested were angiostatin (AS) generated through bPG 
and BPP incubation for 1 hour at 37°C, bPG control as well as BPP control in a 
2%NFDM solution.  
 
The exact mechanism of action through which angiostatin from bPG inhibits 
colon cancer cells development is not yet known, however based on previous 
experiments conducted on human angiostatin we can hypothesize that bovine angiostatin 
may interact with the ATP-synthase located on the surface of colon cancer cells causing 
internal pH to decrease and consequent acidification compromising the cells survival.  
 As seen in other studies, inhibition caused by bPG may be explained by potential 
proteases released by cancerous cells during growth that may interact and cut the protein 
into angiostatin like fragments responsible for the activity observed (Cao Renhai et al. 
1999; Soff Gerald A. 2000; Migita Toshiro et al. 2001). However, since to date no 
anticancer activity on either bovine plasminogen or angiostatin has been studied, it is also 
possible that other mechanism of actions may be involved; perhaps some dissimilarity 
between human and bovine sources cause these molecules to act on different targets.       
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 Dispase is commonly used to separate epidermis from the dermis and it is known 
to hydrolyze collagen and fibrin (Stenn Kurt S. et al. 1989). Additionally, this 
metalloproteinase is known to be produced by the action of Bacillus polymyxa during 
milk storage (Matta Hittu et al. 1998; Larson N. K. et al. 2006). However, no recognized 
anticancer activity has ever been associated with BPP to date. Possibly, BPP modest 
anticancer activity shown in this study may be due by some inhibitory activity not yet 
studied, or since it is known that dispase inhibits cells clumping (Roche, Worthington) 
perhaps this enzyme reduces contact between cancerous cells diminishing their ability to 
communicate or exchange information required for their growth.   
 Despite the exciting results obtained from this study, more investigation is 
required to better understand the mechanism of action behind the anticancer activity 
observed, particularly in the case of bPG and bovine angiostatin.    
 
3.4.2 MELANOMA INHIBITION 
 
Results from the melanoma skin model are summarized in Figure 43. 
Interestingly, many similarities can be perceived to the results obtained for the colon 
cancerous cells inhibition analysis. In fact, comparison of images A, B, D and F in Figure 
43 confirms BPP (B), bovine angiostatin (F) and bPG (D) to display different inhibition 
degrees when compared to the negative control (A), with bovine angiostatin and bovine 
plasminogen showing higher anticancer activity. The same explanations as previously 
provided for the results obtained in the colon cancer analysis, can be applied in this case 
for elucidating the observations obtained in this study.  
Interesting is to observe that human and bovine angiostatin as well as 
plasminogen act in a very similar way. As we can observe from the images below it is not 
possible to identify or confirm which of these molecule showed higher inhibitory activity.  
Lee et al. (1998) showed ability of human angiostatin in increasing human 
melanoma apoptosis in mice (Lee Tong-Young et al. 2009; Mowery Yvonne M. et al. 
2009). According to Lee et al., angiostatin causes a reduced expression of Bcl-2 (a 
mitochondrial antiapoptotic protein) consequently increasing the apoptosis rate. The 
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observations made by Lee et al. may explain the observation made in our study. 
However, further research is necessary before confirming any conclusion.       
    
 
 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43: Melanoma growth inhibition analysis. A) Malignant cells control treated with 
5% SDS; B) analysis of BPP control activity on melanoma cells proliferation; C-D) 
human and bovine plasminogen ability in inhibiting melanoma proliferation; E-F) 
melanoma sample treated with angiostatin (AS) generated by the reaction between BPP 
and human or bovine plasminogen respectively.  
 
A) Control  B) BPP 
C) Human PG D) Bovine PG 
E) Human AS F) Bovine AS 
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3.5 CONCLUSION 
 
The results obtained from the anticancer activity analysis confirm ability of 
angiostatin from bovine source to notably inhibit cancerous melanoma and colon cells 
proliferation when administered at a concentration of 3-16µg/ml (34-182 nM). The exact 
mechanism of action has not been investigated as yet, however due to the similarity in the 
anticancer activity results between human and bovine angiostatin, we can assume bovine 
angiostatin to act through a mechanism similar to that known for human (ATP-synthase 
inhibition, Bcl-2 increase, etc.). Moreover, it would be of interest to understand the 
mechanism behind the anticancer activity seen in plasminogen (both human and bovine). 
If true that enzymes are being produced from cancerous cells responsible for cleaving PG 
and releasing angiostatin, understanding the nature if these enzymes could be of interest 
to determine if bPG could be generated directly from i.e. bacteria in our intestine or other 
enzymes, during milk digestion for example. Other important questions need to be 
examined, such as the ideal PG or angiostatin concentration, as well as treatment 
duration, in order to determine optimal conditions for eventual analysis on animal 
models. Also, would angiostatin be able to survive digestion? And if it does, would the 
body absorb this molecule, or other methods (such as encapsulation) would be necessary 
to ensure angiostatin delivery to its target cells if we were to develop a dairy product 
enriched in this peptide? Some of the answers to these questions were analyzed and 
uncovered in the following chapter.        
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IV. ANGIOSTATIN IN VITRO DIGESTION SURVIVAL ANALYSIS AND 
ANGIOSTATIN PURIFICATION METHODS 
4.1 ABSTRACT 
 
In order to analyze angiostatin‟s ability in surviving digestive enzymes activity, 
angiostatin in buffer or milk system was incubated at stomach as well as small intestine 
simulated conditions. In vitro digestive model was used, as well as investigation on 
ability of each individual digestive enzyme (pepsin, lipase and pancreatin) in hydrolyzing 
the internal bovine plasminogen (bPG) structure at different enzyme:substrate ratios 
(E:S). Results were analyzed through western blotting and sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) techniques. Pepsin showed high affinity 
for angiostatin at E:S ratios of 12:1 used in the in vitro digestion model; however 
hydrolysis was not significant up to a ratio of 1:10 when the enzyme was individually 
analyzed for its affinity for the anticancer peptide, which may represent a more realistic 
proportion. Pancreatin also showed some affinity for angiostatin when independently 
tested; particularly a fragment in the 25 kDa with high immuno-reactivity to anti-bovine 
plasminogen antibody was identified. Knowing that pancreatin consists in a mixture of 
enzymes, mostly trypsin and α-chymotrypsin, activity of these latter were separately 
tested and results indicated trypsin to have very low affinity for angiostatin, while α-
chymotrypsin showed ability in hydrolyzing the fragment of interest even at ratios of 
1:50. Interestingly, the two enzymes generated fragments in the 25 kDa range from bPG 
hydrolysis. These results indicated that not only angiostatin could survive digestion but 
also digestive enzymes (trypsin and α-chymotrypsin) could be generating angiostatin 
related fragments during digestion. Moreover, bovine angiostatin purification was 
conducted through L-lysine affinity chromatography. Results from this experiment 
confirm efficacy of this method to obtain a pure angiostatin solution.    
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4.2 INTRODUCTION  
 
Angiostatin is a peptide generated through bPG hydrolysis from a variety of 
enzymes. Interestingly this protein can assume a variety of forms based on the enzyme 
used to cut and release the internal portion of interest from bPG. This molecule has 
gained increased attention since its discovery in 1994, for its potent ability in inhibiting 
the development of new blood vessels from pre-existing vascularization (this mechanism 
is known as angiogenesis) that would otherwise reach a tumor and support its growth and 
spread through delivery of nutrients and oxygen (O'Reilly Michael S. et al. 1994; Cao 
Yihai et al. 1996; O'Reilly Michael S. et al. 1996; Cao Renhai et al. 1999; Wahl Miriam 
L. et al. 2004; Wahl Miriam L. et al. 2005). Various forms of angiostatin or portions of 
bPG have shown different anticancer mechanism. Due to the success seen in preliminary 
studies in animal models, angiostatin is now in clinical trials (Cao Renhai et al. 1999; 
Wahl Miriam L. et al. 2004). Interestingly, PG is found in the blood of most animals 
since its function, when activated into plasmin, is to hydrolyze blood clots created by 
fibrin. In fact, for a long time methods to inhibit PL activity, that gets transferred from 
the blood of the cow into milk during milk production, have been investigated since this 
enzyme can be responsible for spoilage and reduced quality of many dairy products 
(Bastian Eric D. et al. 1996; Ismail B. et al. 2010). However, no in depth research on the 
ability of bovine plasminogen in being hydrolyzed into anticancer peptides has been 
conducted to date. In our laboratory, we have shown ability of various proteases in 
generating angiostatin like fragments from bPG, and for which in vitro anticancer activity 
resulted to be comparable to that known for human angiostatin. From this study we are 
now further analyzing ability of bovine angiostatin, both in buffer and milk systems, to 
survive digestion. In vitro digestion model from Ferruzzi et al. (2001) was used. 
However, due to incongruity in the information available describing the enzymes 
involved in human digestion and the concentration at which they are released in the 
stomach and small intestine, pepsin, tryspin and α-chymotrypsin were individually tested 
at various E:S ratios. Additionally, ability of these enzymes to generate angiostatin or 
related kringles directly from bPG has been investigated.  
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4.3 EXPERIMENTAL PROCEDURES 
 
4.3.1 REAGENTS AND SOURCES 
 
Bovine plasminogen (product # 416), human glu-plasminogen (product # 412) goat anti-
bovine plasminogen (product # 3416) were purchased from American Diagnostica 
(Greenwich, CT). Dispase I (BPP) (product # D4818), elastase from human leukocytes 
(product # E8140) 3,3‟-diaminobenzidine tetrahydrochloride hydrate (DAB) (product # 
D5637), lipase from porcine pancreas (product # L3126), pepsin from porcine gastric 
mucosa  (product # P7000), bile extract porcine (product # B8631), trypsin from porcine 
pancreas (product # T7409), pancreatin from porcine pancreas (product # P1750), α-
chymotrypsin from bovine pancreas (product # C3142), Cyanogen bromide (product # 
C91492), L-lysine (product # L5501), sepharose (product # 6B100), ethanolamine 
(product # E9508) and 6-aminocaproic acid (product # A2504) were purchased from 
Sigma-Aldrich (St. Louis, MO). Peroxidase AffiniPure Goat Anti-Rabbit IgG (H+L) 
(product # 111-035-003) and Peroxidase Affinipure Rabbit Anti-Goat IgG (H+L) 
(product # 305-035-003) were purchased from Jackson ImmunoResearch Laboratories 
(West Grove, PA). The following electrophoresis and Western blotting reagents and 
materials were purchased from Bio-Rad Laboratories (Hercules, CA): Bio-scale MT 
columns (product # 751-0083), 40% Acrylamide/Bis solution (product # 161-0148), 
Coomassie Brilliant Blue R-250 Staining Solution (product # 161-0436), Precision Plus 
Protein All Blue Standards ( product # 161-0373),  12 and 18 wells Criterion empty 
cassettes (product # 345-9901 and 345-9902), Tris/Glycine/SDS 10X (product # 161-
0772), Laemmli sample buffer (product 161-0737),  tetramethylethylenediamine 
(TEMED, product # 161-0800), Bio-Dot/Bio-Dot SF Filter Paper (product # 162-0161) 
and Sequi-Blot PVDF 0.2 µm membrane (162-0184) as well as the Bio-scale column for 
protein purification (product # 751-0083). Ammonium Persulfate (APS, product # 
BP179-100), Tween 20 (product # BP 337-500), Granular gelatin (product # G8-500) 
were purchased from Fisher Scientific (Hanover Park, IL).   
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4.3.2 PART 1: ANGIOSTATIN IN VITRO DIGESTION SURVIVAL ANALYSIS   
 
4.3.2.1 IN VITRO DIGESTION MODEL  
 
In order to determine ability of angiostatin to survive digestion, stomach and 
small intestine conditions were simulated in vitro. Various protocols were used and 
adapted to the protein concentration of the sample in order to have the most accurate E:S 
ratio that would normally occur in the digestive system. First, in vitro digestion was 
conducted following the model outlined by Ferruzzi et al.(2001) (Green Rodney J. et al. 
2007). One ml of angiostatin solution was first prepared by incubating 0.875mg/ml (9.94 
μM) bPG with 0.1 mg/ml (2.78 μM) BPP for 1 hour at 37°C. At the end of the reaction 
50µl of EDTA were added to the sample which was then boiled for 5 minutes, in order to 
ensure BPP inhibition to avoid further hydrolysis over time that may affect the following 
steps of the experiment. The solution was transferred into a 15 ml falcon tube and 0.9% 
NaCl were added to obtain a 1.5 ml solution volume. The gastric phase was then initiated 
by addition of 0.15 ml of 40 mg/ml (1.16mM) pepsin solution previously prepared in 0.1 
M HCl. The pH was adjusted to 2.0 (± 0.1) by addition of 0.1-1 M HCl. Nitrogen gas was 
flushed on top of the tube, which was subsequently sealed and covered in aluminum foil 
to avoid light penetrating the tube. The sample was incubated for 1hour at 37°C and 
vortexed at low speed every 20 minutes. 
Subsequently, the small intestinal phase was initiated by neutralization of the 
gastric digesta to a pH of 5.3 through addition of 1N NaOH. Small intestinal enzymes 
were then added: 0.23 ml (24 mg/ml) bile extract, 0.115 ml (4mg/ml) pancreatin and 
0.115 ml (2mg/ml, 44.44 μM) of lipase in 100mM NaHCO3. The final pH was further 
adjusted to 7.2 (±0.1) by addition of 0.1 M NaOH, additionally the final volume was 
regulated to 2.5 ml by addition of 0.9% NaCl. The sample was then incubated in the dark 
at 37°C for 2 hours and vortexed every 30 minutes. Prior to analysis, 1:1 Laemmli buffer 
was added and the sample was boiled for approximately 5 minutes and angiostatin 
survival was analyzed through western blotting. Angiostatin digestion was also tested 
when in presence of milk in order to determine whether presence of other peptides in the 
solution would protect angiostatin from being hydrolyzed.   
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4.3.2.2 Ability of individual digestive enzymes in hydrolyzing angiostatin 
 
After stomach and small intestine in vitro digestion analysis, enzymes responsible 
for angiostatin hydrolysis were identified by testing every enzyme individually always 
following the procedures outlined and described by Ferruzzi et al. (2001) and ensuring 
the same E:S ratio for each enzyme tested is maintained in all samples analyzed. Briefly, 
for gastric phase, and thus analysis of pepsin hydrolytic activity on angiostatin, 100µl 
angiostatin containing sample was incubated with 15µl of pepsin (40mg/ml, 1.16mM) 
and 50 µl 0.9% NaCl were added to the solution that was adjusted to a final pH of 2.0 and 
incubated at 37°C for 1 hour. In a similar way 100 µl of angiostatin were added to: 11.5 
µl of pancreatin (4mg/ml), to 11.5 µl of lipase (2mg/ml, 44.44μM) and to 25ul of bile (24 
mg/ml) respectively. These solutions were adjusted to pH 7.2 and the reaction was 
conducted at 37°C for 2 hours. Samples were diluted with 1:1 (v/v) Laemmli buffer and 
analyzed through western-blot.  
Addition of skim milk or NFDM to angiostatin samples in order to analyze the 
effect of presence of additional proteins in protecting angiostatin from being hydrolyzed 
were also studied (experiment procedures are summarized in Figure 44).  
 
 
 
 
 
 
 
Figure 44: experiment procedure scheme for analysis of individual digestive enzymes 
capacity in hydrolyzing angiostatin and the different solutions in which the investigation 
was conducted  
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4.3.2.2.1 VARIOUS E:S RATIOS ANALISIS FOR PEPSIN, TRYPSIN AND α-
CHYMOTRYPSIN  
 
Various concentrations of pepsin, trypsin and α-chymotrypsin were reacted with 
angiostatin in order to analyze the kinetics and the hydrolytic pattern of each enzyme. 
For pepsin digestion, procedures from Astwood et al. (1996) and Fu et al. (2002) 
with some modifications were followed. Simulated gastric fluid (SGF) was prepared (3.2 
mg/ml (92.5 μM) pepsin in 0.03M NaCl pH 1.2). In a 1.5 ml Eppendorf tube 130 µl of 
SGF were heated to 37°C. Subsequently angiostatin was added to obtain a final E:S ratio 
of 12:1 (w/w) (similar to that previously analyzed by Ferruzzi et al.) (Astwood James D. 
et al. 1996; Fu Tong-Jen et al. 2002). Samples were incubated at 37°C and collected after 
0, 1, 5, 10, 15, 20, 30, 60 minutes and diluted in 1:1 Laemmli buffer. Pepsin ability in 
digesting angiostatin was also tested at E:S ratios of 1:100, 1:50, 1:25 and 1:10 (w/w) and 
samples were taken after 1, 5, 10, 15, 20 and 30 minutes incubation and analyzed through 
gel electrophoresis (Sathe Shridhar K. et al. 1997; Roufik Samira et al. 2006).   
Results obtained from the in vitro digestion by individual digestive enzymes 
previously described in section 4.3.2.2, showed pancreatin to exert some hydrolytic 
activity on angiostatin. Since pancreatin is known to be a mixture of trypsin, amylase, 
lipase and other enzymes, in order to better identify which of these proteases is 
responsible for the hydrolysis seen from previous analysis, trypsin and chymotrypsin, 
since two of the major proteolytic digestive enzymes, were individually tested on 
angiostatin and PG breakdown. Various E:S ratios were tested based on Bodwell et al. 
(1980), Sathe et al. (1997) and Roufik et al. (2006) procedures. Briefly, various Trypsin 
or α-Chymotrypsin concentrations were prepared in digestion buffer (0.05M Tris-HCl 
and 0.01M CaCl2 pH 8.1 (Sathe Shridhar K. et al. 1997)) and incubated with angiostatin 
at 37°C for 1 hour. SDS-PAGE as well as western blot were conducted to analyze the 
products obtained from the reaction. Tables 8 and 9 summarize the concentrations used 
for samples preparation.  
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Table 8: Enzyme-substrate ratios used to test ability of trypsin in digesting angiostatin 
E:S (w/w) analyzed Trypsin (final) 
mg/ml 
mg/ml AS (final) 
1:50 0.0067 0.333 
1:20 0.0167 0.333 
1:13 0.025 0.333 
1:10 0.033 0.333 
1:8 0.04167 0.333 
1:6 0.05 0.333 
1:5 0.0583 0.333 
1:3 0.1 0.333 
1:1 0.25 0.25 
3:1 0.5 0.1667 
5:1 0.333 0.0667 
10:1 0.333 0.033 
        
Table 9: Enzyme-substrate ratios used to test ability of α-chymotrypsin in digesting 
angiostatin 
E:S (w/w) 
analyzed 
mg/ml Chymotrypsin 
(final) 
mg/ml AS (final) 
1:100 0.004 0.4 
1:50 0.0067 0.333 
1:20 0.0167 0.333 
1:10 0.033 0.333 
1:5 0.0667 0.333 
1:3 0.1 0.333 
1:1 0.25 0.25 
 
4.3.3 Ability of digestive enzymes in producing angiostatin through plasminogen 
hydrolysis 
 
Analysis of trypsin and α-chymotrypsin hydrolytic products generated from bPG 
breakdown was examined. Similarly to the experiment conducted for angiostatin, various 
E:S ratios were used to determine the affinity of these enzymes for the substrate and also 
to investigate the kinetics of the reaction. Enzyme-substrate ratios of 1:150, 1:75, 1:30, 
1:15, 1:7.5, 1:5 and 1:1.5 were prepared for both trypsin an α-chymotrypsin and 
incubated 1 hour at 37°C. Products obtained from this reaction were analyzed through 
SDS-PAGE and western blotting.  
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4.3.4 PART 2: ANGIOSTATIN PURIFICATION  
 
Purification of angiostatin was conducted through L-lysine sepharose column 
chromatography following procedures outlined by Cao et al. with some modifications 
(Cao Yihai et al. 1996).  
First, the column was prepared by activating sepharose hydroxyl groups with 
CNBr to allow binding to the L-lysine ligands‟ amino groups. Briefly, 10 ml of sepharose 
were washed with 1L of ddwater by vacuum filtration and resuspended in 18ml ddwater. 
Two ml of 0.5M sodium carbonate buffer pH 10.5, were then added and the solution was 
slowly stirred. Under the hood, 1.5 g of CNBr were weighted and added to the stirred 
sepharose ensuring that the pH was being maintained between 10.5 and 11 at all times 
using 4M NaOH.  Once the pH has stabilized and all the CNBr dissolved (approximately 
8min reaction) the solution was filtered using a Buchner funnel, and washed with 2L of 
cold 0.1M sodium bicarbonate buffer pH 9.0 (Mallia A. Krishna et al. 1992; Walker John 
M. 1996). At this point the washed sepharose solution was suspended in 0.1M NaHCO3 
pH 9.0 in a volume equal to that of the original sepharose (10ml). At this time, the 
hydroxyl groups are activated and have high affinity for amino groups. L-lysine was 
subsequently added to the solution at a concentration representing 12% of the final 
volume (1.2g L-lysine which equal 0.008 mol/10ml) under constant stirring at 4°C for 24 
hours. The coupled gel obtained was extensively washed with 0.1M sodium carbonate 
buffer pH 8.5, 1M NaCl and water to remove unbound ligands (samples of sepharose 
before and after coupling were saved in order to measure the absorbance variation and 
determine success of coupling and measure the amount of coupled ligand that will be 
present in the column). Excess active groups (which are still active but failed to bind to 
L-lysine) were blocked by suspending in 10ml 1M ethanolamine pH 9.0 and stirred for 
1h at RT (Cuatrecasas P. et al. 1968; Deutsch Dale G. et al. 1970; Mallia A. Krishna et al. 
1992; Walker John M. 1996). Finally, the gel was washed again with 1M NaCl and a 5 
ml borosilicate glass tube column from Bio-Rad was packed according to the instructions 
provided by the manufacturer.   
     According to Cao et al. (1996), 50mM Tris-HCl pH 8.0 was used as the binding 
buffer while absorbed kringles were eluted using 50mM Tris-HCl containing 200mM 6-
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aminohexanoicacid pH 5.0. After obtaining the chromatogram and collecting the samples 
after purification, in order to identify the peptides purified western blot was conducted.   
 
4.4 RESULTS AND DISCUSSION 
 
4.4.1 PART 1: IN VITRO DIGESTION MODEL 
 
Results obtained from the in vitro model described by Ferruzzi et al. (2001) 
outlined in section 4.3.2.1, can be observed in Figure 45. From this western blot it is 
possible to observe how from this digestion method angiostatin does not survive. 
Immediately after gastric phase (lane 9) no angiostatin remains are observed. It seems 
that pepsin has hydrolyzed all the proteins in the sample. Moreover, it is possible to 
notice, particularly from lane 4, that some of the pepsinogen (MW 43 kDa) present in the 
pepsin (MW 34.5 kDa) solution is slightly cross reacting with the primary anti-bovine 
plasminogen antibody used in this western blot. In fact, if we look at pepsinogen‟s 
molecular structure we will discover a single peptide loop-like structure hold together by 
disulfide bonds (Herriott Roger M. 1962), somewhat comparable to the kringle structures 
seen in plasminogen. Even if pepsinogen‟s molecular weight is very close to that of 
angiostatin, we do not believe its cross reaction will affect the results of our study 
significantly, since as seen in lane 4 in Figure 45, the band observed is slightly 
noticeable, and as we will indeed confirm during the rest of this study, angiostatin 
immunoreactions with anti-bovine plasminogen antibody is much greater and 
consequently can be easily distinguished from pepsinogen.  
In order to better understand exactly which enzymes are responsible for the 
disappearance of angiostatin (as well as the PG present in the sample being digested) 
each enzyme used in this in vitro analysis was individually tested for its hydrolytic 
activity on angiostatin. From the western blot presented in Figure 46, it is interesting to 
notice that, as expected from the results seen in Figure 45, pepsin shows high hydrolytic 
activity on angiostatin, but also pancreatin shows some affinity for the anti-cancer 
protein. Pancreatin appears to be hydrolyzing all the peptides in the sample with 
molecular weight higher than 30 kDa to generate smaller fragments in the 25 kDa range, 
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perhaps a combination of kringles, showing high immunoreaction. A less credible finding 
was to discover that lipase also show ability in hydrolyzing angiostatin (lane 11). 
Strangely, lipase exhibits the same hydrolytic pattern as pancreatin. In order to 
confirm these results and ensure that no errors took place during the experiment, this 
same experiment was conducted in triplicates, each time with new reagents (enzymes 
solutions were freshly prepared) but the same observation made for western blot in 
Figure 46 were obtained. At this point, a plausible explanation to this phenomenon may 
be that the lipase used in this study is not pure enough. Casein SDS-PAGE was 
conducted (Appendix F) and results confirmed indeed some contamination. Zone of 
clearances near 25 and 50 kDa, indicating enzyme caseinolytic activity, were observed 
both for pancreatain and lipase. These finding indicate that most probably some of the 
enzymes present in pancreatin and responsible for angiostatin hydrolysis are also present 
in lipase. Moreover, according to the manufacturer, protease presence may not be 
surprising in purchased lipase product, since it may be difficult to obtain a lipase protease 
free when purified from the pancreas. For the rest of the study, since it is known lipase to 
be specific for lipids and not proteins, we will not discuss or examine its activity any 
further. 
When angiostatin digestion is conducted in NFDM (Figure 47), the additional 
proteins present in the sample help protect somewhat the hydrolysis of angiostatin by the 
hydrolytic action of pancreatin, since generation of 25kDa fragments is not as evident and 
peptides in the 37kDa area are still visible, contrarily to observations made when 
digestion was conducted in buffer. On the other hand, milk proteins do not help protect 
angiostatin‟s hydrolysis by the action of pepsin; as shown in lane 6 of the gel in Figure 
47, all the proteins bands seem to have disappeared. Similar results can also be observed 
when the experiment is conducted in a skim milk system. In none of the experiments bile 
has shown proteolytic activity since bile is known to be a mixture of salts secreted by the 
liver into the small intestine to help lipids digestion.     
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Figure 45: Western blot analysis of angiostatin digested through in vitro digestive model 
procedures. Lane 1: molecular weight standard; lane 2: bPG control (0.175 mg/ml); lane 
3: 2% NFDM control; lane 4: pepsin control (1.82 mg/ml); lane 5: pancreatin (0.092 
mg/ml) control; lane 6: bile (1.104 mg/ml) control; lane 7: lipase (0.046 mg/ml) control; 
lane 8: angiostatin (produced by interaction between bPG (0.875 mg/ml) and BPP 
(0.1mg/ml)) control; lane 9: digestion of angiostatin in 2% NFDM after gastric phase; 
lane 10: digestion of angiostatin in 2% NFDM after small intestine phase; lane 11: 2% 
NFDM gastric phase digestion control; lane 12: 2% NFDM small intestine phase 
digestion control.       
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 46: Western blot analysis on the of angiostatin digestion by the action of various 
digestive enzymes. Lane 1: molecular weight standard; lane 2: bPG (0.175 mg/ml) 
control; lane 3: pepsin control (1.82 mg/ml); lane 4: bile (1.104 mg/ml) control; lane 5: 
lipase (0.046 mg/ml) control; lane 6: pancreatin (0.092 mg/ml) control; lane 7: 
angiostatin control (produced through bPG hydrolysis from BPP); lane 9-12: angiostatin 
digested by the action of pepsin, bile, lipase and pancreatin respectively.      
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Figure 47: Western blot analysis of angiostatin digestion when in presence of NFDM. 
Lane 1: molecular weight standard; lane 2: bPG control (0.175 mg/ml); 1% NFDM 
control; lane 4: angiostatin in buffer control (obtained through bPG hydrolysis by the 
action of BPP for 1 hour at 37°C); lane 5: angiostatin in 2% NFDM; lane 6-9: angiostatin 
in NFDM digested by the action of pepsin, bile, lipase and pancreatin respectively.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 48: Western blot analysis of digestion of angiostatin in skim milk by the action of 
various digestive enzymes. Lane 1: molecular weight standard; lane 2: bPG control 
(0.175mg/ml); lane 3: skim milk (diluted 1:5 in ddwater) control; lane 4: angiostatin 
control (produced through bPG hydrolysis by the action of BPP at 37°C for 1 hour); lane 
5: angiostatin in skim milk control; lane 6-9: angiostatin in skim milk digested by the 
action of pepsin, bile, lipase, and pancreatin respectively.   
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4.4.2 Analysis of the interaction between various E:S ratios for pepsin, trypsin, α-
chymotrypsin and angiostatin  
 
4.4.2.1 PEPSIN 
 
Observations made from the in vitro analysis previously analyzed, infer that 
angiostatin cannot survive gastric phase due to pepsin‟s high hydrolytic activity. Before 
confirming such observation it would be of interest to investigate more in depth the 
hydrolytic pattern and the affinity of pepsin to angiostatin, at what E:S ratio does 
angiostatin start being hydrolyzed? Does a E:S ratio of 12:1 really mimic the digestion 
conditions, particularly when such a small amount of protein is being analyzed in a pure 
form and not in a real food system?  
First, using a ratio of 12:1, as suggested by Ferruzzi et al. (2001), we examined 
angiostatin‟s proteolytic pattern over time. As Figure 49 indicate, after only 10 minutes, 
pepsin breaks down angiostatin into a 25 kDa fragment that will then disappear in the 
following 10 minutes of the reaction.  
From the literature a lot of disagreement is found in the determination of an ideal 
E:S ratio to study digestion of proteins by the action of pepsin. Ranges from 12:1 to 
1:7500 are observed (Hur Sun Jin et al. 2011). Due to this great incongruity, we decided 
to analyze a broad range of E:S ratios from 1:100 to 1:10 based on in vitro digestibility 
experiment conducted by Astwood et al. (1996), Sathe et al (1997) and Roufik et al. 
(2006). As results in Figure 50 and 51 reveal, even when pepsin is reacted at an E:S ratio 
of 1:10 no significant hydrolysis of angiostatin seems to occur. In this images it s possible 
to notice angiostatin having a higher molecular weight, this is because the reaction is 
conducted at pH 2 causing the molecule to denature and appear to have a higher 
molecular weight. Interesting is to notice that bPG is hydrolyzed at a much higher rate 
than angiostatin. In fact, a darker band is observed over time in the 25 kDa range even 
though angiostatin concentration does not significantly decrease over time.  Therefore 
according to these findings, it is evident that more data is necessary before making any 
assertion about the fate of angiostatin in the stomach if an in vitro procedure is to be 
accurate. This work demonstrates that further in vitro methods of analysis need to be 
conducted in order to determine the more accurate E:S ratios mimicking real digestion 
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conditions and at what concentration should angiostatin be added to a dairy product if we 
were to develop a cancer preventive food.                 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 49: SDS-PAGE visualization of proteolytic fragments obtained through 
angiostatin hydrolysis by the action of pepsin at E:S ratio 12:1. Lane 1: molecular weight 
standard; lane 2: angiostatin (AS) control (obtained through hydrolysis of bPG by the 
action of BPP for 1 hour at 37°C); lane 3: pepsin (P) control (1mg/ml); lane 4-11: 
angiostatin hydrolysis by the action of pepsin after 0, 1, 5, 10, 15, 20, 30 and 60 minutes 
incubation at 37°C.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 50: SDS-PAGE analysis of angiostatin hydrolysis by the action of pepsin at pH 2 
and E:S ratio of 1:100 and 1:50. Lane 1: molecular weight standard; lane 2: angiostatin 
(AS) control (0.4 mg/ml) (obtained from the reaction between bPG and BPP for 1 hour at 
37°C); lane 3: pepsin (P) control (0.004mg/ml); lane 4-9: angiostatin digestion by the 
action of pepsin at an E:S ratio of 1:100 after 1, 5, 10, 15, 20 and 30 minutes incubation 
at 37°C; lane 10: pepsin control (0.008mg/ml); lane 11-16: angiostatin digestion by the 
action of pepsin at an E:S ratio of 1:50 after 1, 5, 10, 15, 20 and 30 minutes incubation at 
37°C. Bands in the 37kDa area correspond to angiostatin (AS). 
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Figure 51: SDS-PAGE analysis of angiostatin hydrolysis by the action of pepsin at pH 2 
and E:S ratio of 1:25 and 1:10. Lane 1: molecular weight standard; lane 2: angiostatin 
(AS) control (0.4 mg/ml) (obtained from the reaction between bPG and BPP for 1 hour at 
37°C); lane 3: pepsin (P) control (0.016mg/ml); lane 4-9: angiostatin digestion by the 
action of pepsin at an E:S ratio of 1:25 after 1, 5, 10, 15, 20 and 30 minutes incubation at 
37°C; lane 10: pepsin control (0.04mg/ml); lane 11-16: angiostatin digestion by the 
action of pepsin at an E:S ratio of 1:10 after 1, 5, 10, 15, 20 and 30 minutes incubation at 
37°C. Bands in the 37kDa area correspond to angiostatin (AS). 
 
4.4.2.2 TRYPSIN   
 
The possibility of trypsin being responsible, at some degree, in the angiostatin 
hydrolysis previously seen in the pancreatin samples was analyzed. Some activity was 
indeed discovered.  The pancreatin to angiostatin ratio used in section 4.3.2.2 was 
approximately 1:1 (w/w). Since pancreatin contains a variety of enzymes other than 
trypsin, we would assume the ratio between trypsin and angiostatin to be less than 1. 
Based on these assumptions, trypsin activity in pancreatin would be the one observed in 
either lane 4, 5 or 6 of Figure 53 or some other ratio analyzed in Figure 52. From these 
images it is clear that at ratios of 1:50 (w/w) to approximately 1:5 (w/w) no significant 
angiostatin hydrolysis occurs, however a thick band in the 25 kDa band with strong 
immunoreactivity for anti-bovine plasminogen antibody (Figure 54) is observed and it 
seems to be produced primarily through hydrolysis of bPG present in the samples.  
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A dilution effect may be misled into hydrolytic activity. In fact the disappearance 
of angiostatin observed in Figure 53 from lane 7 to 10 is due to a reduction in angiostatin 
concentration. As outlined in Table 8, angiostatin concentration is constant (0.333 mg/ml) 
until E:S ratio 1:3 is reached, at higher ratios lower angiostatin is used. Nevertheless, 
analysis of the western blot (which technique is characterized by a higher detection limit 
than SDS-PAGE) shows that even at 1:1 ratio angiostatin is well characterized by a thick 
band at its corresponding molecular weight range.      
From these observations it is possible to conclude that at E:S ratios lower than 1, 
trypsin does not significantly hydrolyze angiostatin. As in the case for pepsin, incongruity 
in the best E:S ratio representative of real digestive conditions are observed. This 
difficulty is mostly caused by variations among individuals. In fact according to Dr. 
McClements “The human body… is very complex and varies from person to person, 
depending on age, sex, health status, and type of meal, so it is difficult to accurately 
simulate the digestion process” (Mermelstein Neil H. 2010). Ratios from 1:100 to 12:1 
are found in the literature making conclusions from our observations very dissimilar 
based on which procedure is being considered. For example, if we make conclusions 
based on Sathe et al. (1997) study, we would be thrilled to find out that at a ratio of 
1:100, trypsin affinity for the peptide of interest is extremely low; angiostatin will with 
no doubt survive trypsin activity during digestion. On the other hand, if conclusions are 
made based on another study conducted by Bodwell et al. (1980), we would probably 
need to consider encapsulation methods to protect angiostatin from being digested by 
trypsin (as well as pepsin and chymotrypsin). In order to be able to make accurate 
conclusions, ideal E:S ratio needs to be determined or usage of a TNO-intestinal model or 
in vivo digestion may be considered for more conclusive observations.      
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Figure 52: SDS-PAGE analysis of angiostatin digestion by the action of trypsin at various 
E:S after 1 hour at 37°C. Lane 1: molecular weight standard; lane 2: angiostatin (AS) 
control (obtained from bPG hydrolysis by the action of BPP after 1hour at 37°C); lane 3: 
trypsin (T) control (0.175mg/ml); lane 4-10: angiostatin interaction with trypsin at E:S 
ratios of 1:50, 1:20, 1:13, 1:10, 1:8, 1:6 and 1:5 respectively.      
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 53: SDS-PAGE analysis of the products generated by the reaction between 
angiostatin and trypsin at various E:S. Lane 1: molecular weight standard; lane 2: 
angiostatin (AS) control (obtained by bPG hydrolysis by the action of BPP at 37°C for 1 
hour); lane 3: trypsin (T) control (0.75 mg/ml); lane 4-10: angiostatin interaction with 
trypsin at E:S ratios 1:10, 1:5, 1:3, 1:1, 3:1, 5:1 and 10:1 respectively.     
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Figure 54: Western blot analysis of the products generated by the reaction between 
angiostatin in skim milk and trypsin at various E:S. Lane 1: molecular weight standard; 
lane 2: angiostatin (AS) control (obtained by bPG hydrolysis by the action of BPP at 
37°C for 1 hour); lane 3: skim milk (SM) control (diluted 1:5 v/v in ddwater) lane 4: 
trypsin (T) control (0.5 mg/ml); lane 5-11: angiostatin interaction with trypsin at E:S 
ratios 1:100, 1:50, 1:20, 1:10, 1:5, 1:3 and 1:1 respectively.     
 
4.4.2.3 α-CHYMOTRYPSIN 
 
As previously mentioned, α-chymotrypsin was also another enzyme possibly 
involved in the hydrolysis of angiostatin seen in pancreatin. Similar to trypsin, various 
E:S ratios were analyzed and results can be observed in Figures 55 and 56. Compared to 
trypsin, α-chymotrypsin showed much higher affinity for angiostatin since at a ratio of 
only 1:50, hydrolysis of this molecule is observed; and at a 1:10 ratio all the proteins in 
the sample seem to be completely hydrolyzed (between 1:50 and 1:3 no dilution effect is 
seen since the same angiostatin concentration is used; refer to Table 9 for more 
information). Interestingly, also in this case a fragment in the 22 kDa area is observed. 
However, when analyzing the results obtained from the SDS-PAGE a very thick and dark 
band corresponding to this MW is seen, but when examining the results from the western 
blot, this band is barely noticeable. Perhaps the α-chymotrypsin hydrolyzes angiostatin or 
bPG to release fragments for which the anti-bovine plasminogen antibody is hardly 
capable of recognizing. This same phenomenon will be observed later from the 
interaction between α-chymotrypsin and bPG.    
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Figure 55: SDS-PAGE analysis of the products generated by the reaction between 
angiostatin and α-chymotrypsin at various E:S ratios. Lane 1: molecular weight standard; 
lane 2: angiostatin (AS) control (obtained by bPG hydrolysis by the action of BPP at 
37°C for 1 hour); lane 3: α-chymotrypsin (α–C) control (0.5 mg/ml); lane 4-10: 
angiostatin interaction with trypsin at E:S ratios 1:100, 1:50, 1:20 1:10, 1:5, 1:3 and 1:1 
respectively.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 56: Western blot analysis of the products generated by the reaction between 
angiostatin in skim milk and α-chymotrypsin at various E:S. Lane 1: molecular weight 
standard; lane 2: angiostatin (AS) control (obtained by bPG hydrolysis by the action of 
BPP at 37°C for 1 hour); lane 3: skim milk (SM) control (diluted 1:5 v/v in ddwater) lane 
4: α-chymotrypsin (α-C)control (0.5 mg/ml); lane 5-11: angiostatin interaction with α-
chymotrypsin at E:S ratios 1:100, 1:50, 1:20, 1:10, 1:5, 1:3 and 1:1 respectively.     
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4.4.3 Ability of digestive enzymes in producing angiostatin through plasminogen 
hydrolysis 
 
An interesting question can be asked with regards to the creation of a dairy 
product enriched in angiostatin: is our body capable of producing angiostatin directly 
from bPG in milk during digestion? If true, this would perhaps explain some observations 
made from epidemiological studies in which it has been confirmed that people who 
regularly consume milk tend to have lower risk of developing colon cancer, but for which 
the specific compound (lactose, calcium, fat or other) responsible in imparting this health 
benefit has yet to be discovered (Järvinen R. et al. 2001; Cho Eunyoung et al. 2004).  
 
4.4.3.1 TRYPSIN  
 
As previously mentioned, the exact amount of trypsin released in the small 
intestine during digestion has not been determined. In order to analyze the affinity and 
hydrolytic patter between trypsin and bovine plasminogen, various E:S ratios from 1:150 
to 1:1.5 were examined. From Figure 57, it is possible to notice that a simple and clear 
reaction occurs from this interaction. Trypsin starts showing high affinity for bPG at 
ratios of 1:15; at higher ratios bPG is completely hydrolyzed. From both the SDS-PAGE 
and the western blot seen below, trypsin appears to generate a fragment in the 50kDa area 
(probably PL) and a 25kDa peptide contemporaneously and with high immunoreactivity 
for anti-bovine plasminogen antibody. Knowing that 25kDa could correspond to kringles 
2-3, known to be able to inhibit endothelial cells proliferation (Ji Weidong-richard et al. 
1998), or to some other kringle combination, it would be of interest to investigate in the 
future the sequence of this fragment generated by trypsin and its ability in inhibiting 
cancerous cells growth.   
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Figure 57: SDS-PAGE visualization of the products generated by trypsin during bPG 
hydrolysis at various E:S ratios after 1 hour at 37°C. Lane 1: molecular weight standard; 
lane 2: bPG control (0.25 mg/ml); lane 3: trypsin (T) control (0.5mg/ml); lane4: reaction 
between bPG and trypsin at E:S ratios 1:150, 1:75, 1:30, 1:15, 1:7.5, 1:5 and 1:1.5 
respectively.   
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 58: Western blot visualization of the products generated by trypsin during bPG 
hydrolysis at various E:S ratios after 1 hour at 37°C. Lane 1: molecular weight standard; 
lane 2: bPG control (0.25 mg/ml); lane 3: trypsin (T) control (0.5mg/ml); lane 4: reaction 
between bPG and trypsin at E:S ratios 1:150, 1:75, 1:30, 1:15, 1:7.5, 1:5 and 1:1.5 
respectively.   
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4.4.3.2 α-CHYMOTRYPSIN 
 
Similarly to trypsin, α-chymotrypsin was tested on its ability in bPG hydrolysis. 
From the results obtained, and presented in Figure 59, chymotrypsin shows very similar 
affinity to bPG, to that previously seen in trypsin under same experimental conditions. 
However, contrarily to trypsin, chymotrypsin main products are fragments with 
molecular weight around 25-22 kDa. Plasmin (50kDa) is also produced, but as the E:S 
ratio increases, PL gets hydrolyzed into smaller fragments. Despite the bands in the 25 
kDa area being very dark and thick, the western blot does not translate into a dark brown 
band as expected. The immunoreaction between the primary antibody and these lower 
MW peptides is not as strong as one would imagine. Most probably this phenomenon is 
caused by the fact that MW of the enzyme is in the same range as that of the fragments 
observed (Figure 59 lane 3), explaining why a thicker band in the gel but not in the 
western blot is observed.  
As in the case of trypsin, it would be of interest to further analyze what portion of 
bPG the fragments obtained belong, and test for their anticancer activity to investigate 
whether or not angiostatin related fragments are produced in the human body during 
digestion.       
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
Figure 59: SDS-PAGE visualization of the products generated by α-chymotrypsin during 
bPG hydrolysis at various E:S ratios after 1 hour at 37°C. Lane 1: molecular weight 
standard; lane 2: bPG control (0.25 mg/ml); lane 3: α-chymotrypsin (α-C) control 
(0.5mg/ml); lane4: reaction between bPG and α-chymotrypsin at E:S ratios 1:150, 1:75, 
1:30, 1:15, 1:7.5, 1:5 and 1:1.5 respectively. 
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Figure 60: Western blot visualization of the products generated by α-chymotrypsin during 
bPG hydrolysis at various E:S ratios after 1 hour at 37°C. Lane 1: molecular weight 
standard; lane 2: bPG control (0.25 mg/ml); lane 3: α-chymotrypsin (α-C) control 
(0.5mg/ml); lane 4: reaction between bPG and α-chymotrypsin at E:S ratios 1:150, 1:75, 
1:30, 1:15, 1:7.5, 1:5 and 1:1.5 respectively. 
  
4.4.4 PART2: ANGIOSTATIN PURIFICATION  
 
Purification of bovine angiostatin was for the first time successfully conducted in 
our laboratory.  Figure 61 and 62 shows the western blot obtained from the samples 
recovered after being purified through affinity column chromatography and the 
corresponding chromatogram. Purification was conducted in duplicates and the results for 
both tries are shown in the western blot below. From the first try in angiostatin 
purification (lanes 3 to 5), it is possible to observe how a single band in the 37kDa area is 
seen in lane 5 of the western blot corresponding to the sample recovered from the elution 
phase. A less evident PL residue can be also seen in the 50kDa MW for the same sample. 
Similar results are seen for the second attempt in angiostatin purification, in which the 
same procedures as the ones conducted in the first try were followed. However, from the 
second try a lot more protein is recovered, particularly in the 75-50kDa MW, from the 
sample retrieved right after injection into the column (lane 6). Contrarily to the second 
purification attempt, during the first try, due to difficulties in setting the equipment and 
adjusting the background noise seen in the readings, more binding buffer was used 
MW        bPG                α-C     1:150  1:75     1:30     1:15     1:7.5     1:5       1:1.5    
250 
150 
100 
 
75 
 
 
50 
 
 
37 
 
 
25 
 
20 
 
bPG 
  
100 
 
causing the sample to being further diluted as well as lower flow rate into the column. 
These differences among these two tries, may indicate that under the conditions (sample 
protein concentration and flow rate) initially planned on using, saturation of the column 
may occur, inhibiting the desired protein to have enough time or space to interact with the 
ligands. This may explain why in lane 8 less angiostatin was recovered from the eluted 
sample, and why the pick in the chromatogram resulted to be very small.  
In conclusion, from our first attempt in bovine angiostatin purification it can be 
confirmed that L-lysine column chromatography is an adequate method to employ and 
the binding and elution buffers used are suitable for this experiment. However, 
adjustment on the flow rate or different size column, according to the protein 
concentration in the sample will be require in the future in order to maximize protein of 
interest and ligand interaction to avoid saturation and obtain pure angiostatin.             
 
 
 
 
 
 
 
 
Figure 61: Western blot of samples recovered after L-lysine affinity column 
chromatography. Lane 1: molecular weight standard; lane 2: interaction between BPP and 
bPG at 37°C after 1 hour incubation (control).  Lanes 3 to 5 represent first purification try 
and samples recovered at retention times: 0 to 8.8 minutes; 8.8 to 14.3 minutes; 14.3 to 
20 minutes respectively. Lanes 6 to 8 represent samples collected during second 
purification attempt at retention times: 0 to 5.6 minutes; 5.6 to 10.0 minutes; 10.0 to 20.8 
minutes respectively      
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Figure 62: Chromatogram generated during purification of angiostatin from bovine 
plasminogen and BPP through L-lysine affinity column chromatography. The first pick 
obtained at 2.83 minutes retention time represent proteins recovered during binding 
phase, while the second pick at 13.73 minutes represent proteins recovered during elution 
phase.    
 
4.5 CONCLUSION 
 
Results from in vitro digestion initially implied inability of angiostatin to survive 
digestion. Further examination on affinity of individual enzymes to the anticancer peptide 
showed pepsin to be the enzyme responsible for completely hydrolyzing angiostatin 
under stomach conditions and at 12:1 enzyme substrate ratio. Nevertheless, at various E:S 
ratios, pepsin did not show significant hydrolysis even at a proportion of 1:10, which may 
represent a more credible relationship between pepsin and the substrate that may occur in 
the stomach during digestion.  
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When individually analyzed, pancreatin also showed some hydrolytic activity on 
angiostatin. Knowing that pancreatin consist in a mixture of enzymes, with proteases 
being mostly trypsin and α-chymotrypsin, individual analysis of these two proteases was 
conducted to better identify the enzyme responsible for the hydrolytic activity observed. 
Results indicated α-chymotrypsin to have higher affinity for the substrate than trypsin, 
since even at very low E:S ratios (1:50) α-chymotrypsin showed angiostatin hydrolysis, 
contrarily to trypsin for which ratios of 1:3 were needed to see a similar effect.  
In a similar way, these two digestive proteases were tested for their ability in 
hydrolyzing and generating anti-cancer fragments directly from bPG. As seen for 
angiostatin, α-chymotrypsin showed higher hydrolytic activity than trypsin. However, 
ability in generating fragments in the 25kDa area, confirmed to belong to bPG internal 
structure, was seen for both   trypsin and α-chymotrypsin. It would be of interest in the 
future to further analyze the structure of these fragments obtained, and to examine their 
ability in inhibiting growth of cancerous cells. However, due to incongruity in the 
literature regarding the concentration of each digestive enzyme released in the stomach 
and small intestine, in order to better understand what really occurs during digestion, 
further in vivo analysis are suggested.  
Subsequently, ability of bovine angiostatin to be purified through column 
chromatography using L-lysine affinity, as it is used to purify human angiostatin, was 
proven to be an efficient method to obtain a much purified molecule.      
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V. OVERALL CONCLUSION 
 
From this study it was possible to confirm ability of generating angiostatin like 
fragments from bPG through a variety of enzymes. The enzyme that showed higher 
ability in generating this 37 kDa fragment, from the bovine source of the fibrinolytic 
zymogen, was elastase. In contrast, BPP showed higher affinity for hPG, since less 
incubation time as well as 10 fold less concentrated enzyme were required to obtain the 
fragment of interest compared to bPG. On the other hand, when comparing BPP with 
elastase and their ability in generating the bovine form of angiostatin, BPP reaction was 
much shorter, only one hour compared to the 8 hours required by elastase. However, the 
amount of the fragment produced was considerably higher from the action of elastase 
than BPP.  
Moreover, from sequence analysis techniques, it was possible to confirm ability 
of BPP in generating angiostatin K1-4 and mini-PG having molecular weight of 37 kDa 
and 34 kDa respectively.   
Discovery of Bacillus strains capable of generating proteases showing bPG 
affinity was also possible from this study. Particularly interesting was to uncover ability 
of some Bacillus, such as B.coagulans ATCC 7050, of releasing a fragment in the 37 kDa 
area showing  immunoreaction with the anti-bovine plasminogen antibody utilized to 
conduct western blotting analysis. 
From the anticancer activity conducted on human melanoma and colon cancerous 
cells, results showed significant activity in growth inhibition of these malignant cells by 
the action of bovine angiostatin when administered at concentrations of 3-16 µg/ml. 
Comparison of this activity between human and bovine sources of angiostatin, showed 
resemblance among the results obtained, inferring that the two molecules may act 
through the same mechanism and have similar affinity for specific targets located on 
cancerous cells. Additionally, human and bovine PG also showed ability in inhibiting 
cancerous cells growth. Knowing that malignant cells secrete enzymes necessary for the 
support of their metabolism, it would be of interest to further examine if the anticancer 
activity seen in PG samples is not actually due to angiostatin produced by the action of 
the proteases released during cancerous cells growth. 
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 From the in vitro digestion analysis, results at first suggested inability of 
angiostatin to survive digestion. Individual analysis of digestive enzymes in hydrolyzing 
angiostatin showed pepsin to be responsible for this observation. However, in order to 
further analyze the interaction between pepsin and angiostatin various E:S ratios were 
analyzed. High hydrolysis was observed for ratios of 12:1 pepsin:angiostatin (ratio used 
for the in vitro analysis). This ratio however may not mimic real stomach conditions, 
particularly since small amounts of protein and in a pure form are being used in this 
study. When this ratio is reduced to 1:10 no significant hydrolysis, even after 1 hour 
incubation, is observed. Since determination of real digestive conditions (i.e. amount of 
digestive enzymes involved) are still under investigation due to difficulties related to 
variability among individuals and the numbers of factors that need to be considered, in 
order to verify validity of these results in vivo analysis is suggested. 
 Regardless of the uncertain amount of specific digestive enzymes released in the 
stomach and small intestine during digestion, analysis on the ability of trypsin and α-
chymotrypsin in hydrolyzing angiostatin or bPG was conducted. Various E:S ratios were 
examined, and results showed α-chymotrypsin to have higher affinity, both for bPG and 
angiostatin, that trypsin. Nevertheless, both proteases were able to generate a fragment in 
the 25 kDa area belonging to the internal portion of PG. Knowing that each kringle or 
various kringle combinations have shown to exert some anticancer activity, it would be of 
interest to further investigate the structure and possible anticancer activity of these 
fragments, to analyze if peptides capable of cancer prevention can be generated directly 
in our body during milk digestion.                 
Finally, methods to purify bovine angiostatin were confirmed. Affinity l-lysine 
column chromatography, used in the purification of human angiostatin, resulted to be an 
effective method to obtain pure bovine angiostatin.  
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VI. FUTURE RESEARCH RECOMMENDATIONS 
 
Results obtained from this study open a new area of investigation, particularly in 
the food science field. Before being able to generate a food product enriched in 
angiostatin, it is necessary to further investigate what form of the molecule exert the 
higher anticancer activity (i.e. K1-4, K1-3 or other).  
Also, it remains to be elucidated what concentration of angiostatin would be ideal 
to have a significant anticancer activity, as well as what type of cancer is more 
susceptible to bovine angiostatin. The mechanism through which this molecule acts to 
stop cancerous cells growth and spread also requires deeper investigation.   
Additionally, it would be of interest to better understand what conditions and 
nutrients cause Bacillus to generate proteases capable of releasing angiostatin like 
fragments from plasminogen. Identification of the genes activated under ideal conditions 
could be then be used to genetically modify LAB that can be subsequently used to 
produce dairy products, i.e. yogurt, enriched in angiostatin.   
Moreover, knowing that in vitro analysis not always reflect in vivo conditions, 
tests on animals and humans are necessary to prove validity of the results obtained in the 
laboratory.  
Subsequently, further analysis on angiostatin digestion survival is highly 
recommended. Particularly of interest is to further study the ability and amount of this 
peptide to be absorbed by the body during digestion and if digestive enzymes can indeed 
interact directly with bPG in milk during digestion to generate potential anticancer 
peptides. 
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APPENDIX A. Supplemental data corresponding to Chapter 2: Bovine plasminogen 
proteolytic fragments generated by Bacillus polymyxa protease  
 
A.1 Objective  
 
To analyze the kinetics of the reaction between BPP and bPG through 
Lineweaver-Burk and Hanes-Woolf Plot.  
 
A.2 Materials and Methods 
 
All materials and methods have been described in Chapter 2, section 2.3.1 
(reagents and sources), 2.3.2 (sample preparation), and 2.3.2.3.1 (SDS-PAGE). 
 
A.3 Results and Conclusions 
 
Looking at the saturation curve in Figure 63, it is possible to determine Vmax as 
442.13 int/min that is reached when BPP is reacted at 0.1 mg/ml with 0.625 mg/ml of 
bPG. Subsequently from the Lineweaver-Burk observed in Figure 64, Vmax and Km are 
identified as 1203.369 and 0.977 respectively, while from the Hanes-Woolf Plot (Figure 
65), Vmax result to be equal to 1000 and Km to 0.8. The results obtained from these two 
kinetic analyses are not in agreement with the observation made from the SDS-PAGE 
obtained in Figure 11. Knowing that a large Km (which can assume values between 0 and 
1) indicate little affinity of the enzyme for the substrate, values of Km of 0.977 or 0.8 as 
those obtained in this kinetic analysis, imply that BPP has little to no affinity for bPG. 
However, from the gel images obtained throughout this study it is possible to confirm 
that it is not the case, and that BPP actually shows high affinity for bPG. An explanation 
to the incongruity between these results may be the values used to construct the graphs in 
Figure 64 and 65. In general, enzyme and substrate concentration is used to examine the 
kinetics of a reaction. In our case however this was not possible, quantification of the 
substrate was analyzed through band intensity measure from the SDS-PAGE through 
densitometry. Perhaps the intensity readings made from the densitometer are not accurate 
enough to translate what observed in the gel into a graph.   
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Figure 63: Saturation curve obtained from the reaction between BPP (0.1 mg/ml) and 
various bPG concentrations (0.25, 0.375, 0.5 and 0.625 mg/ml) after 1 hour incubation at 
37°C 
 
Figure 64: Lineweaver-Burk obtained by plotting the inverse of the initial velocities from 
the interaction between various bPG concentrations (0.25, 0.375, 0.5 and 0.625 mg/ml) 
and BPP (0.1 mg/ml) after 1 hour incubation at 37°C and the inverse of bPG 
concentration used 
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Figure 65: Hens-Woolf plot obtained by plotting bPG concentration vs. the value 
obtained by dividing the substrate concentration with the corresponding initial velocity 
observed between BPP and bPG interaction  
 
 
APPENDIX B. Supplemental data corresponding to Chapter 2: Bovine plasminogen 
proteolytic fragments generated by Bacillus polymyxa protease  
 
B. 1. Objective 
Determine sequence analysis of bands of interest obtained from BPP and bPG 
hydrolysis  
 
B. 2. Results and Conclusions 
From the data obtained from sequence analysis obtained through LCMS 
conducted at UC Davis proteomics core, it was possible to identify peptides generated at 
35, 37 and 50 kDa, after reaction between BPP and bPG, as mini-PG, angiostatin K1-4 
and PL respectively. Even if results can be observed in Figures 66, 67 and 68, for more 
accurate interpretation only fragments that resulted to have an actual minus calculated 
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ENSBTAP00000001674 (100%), 91,121.3 Da
Plas minoge n precurs or (EC 3.4.21.7) [Contains: Plas min heavy chain A; Activation pe ptide; Plas min heavy chain A, short form ; Plas min light chain B]. [Source:Uniprot/SWISSPROT;Acc:P06868]
67 unique  peptide s, 82 unique spectra, 153 total spectra, 529/810 am ino acids (65% coverage )
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ENSBTAP00000001674 (100%), 91,121.3 Da
Plas minoge n precurs or (EC 3.4.21.7) [Contains: Plas min heavy chain A; Activation peptide ; Plasm in heavy chain A, short form ; Plasm in light chain B]. [Source:Uniprot/SWISSPROT;Acc:P06868]
73 unique  peptide s, 85 unique  spe ctra, 178 total spectra, 495/810 am ino acids (61% coverage)
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peptide mass (PPM) between ±200 were considered in order to examine only peptides 
showing higher probability.       
 
   
 
 
 
 
 
Figure 66: Sequence analysis of 35 kDa fragment generated through bPG hydrolysis by 
the action of BPP (0.1mg/ml) after 1 hour incubation. The colored amino acids represent 
the sequence coverage of bPG, and in green are observed post-translational modifications   
 
 
 
 
  
 
 
 
Figure 67: Sequence analysis of 37 kDa fragment generated through bPG hydrolysis by 
the action of BPP (0.1mg/ml) after 1 hour incubation. The colored amino acids represent 
the sequence coverage of bPG, and in green are observed post-translational modifications   
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Figure 68: Sequence analysis of 50 kDa fragment generated through bPG hydrolysis by 
the action of BPP (0.1mg/ml) after 1 hour incubation. The colored amino acids represent 
the sequence coverage of bPG, and in green are observed post-translational modifications  
 
APPENDIX C. Additional data corresponding to Chapter 2: Generation of 
angiostatin from bovine plasminogen hydrolysis by the action of Bacillus and 
Lactobacillus originated proteases 
 
C.1. Objective 
 
To analyze ability of Lactobacillus in generating proteases when grown in MRS-
5% UHT 
 
C.2. Reagents and Sources 
 
All materials and methods have been described in Chapter 2, sections 2.3.1 
(reagents and sources), 2.3.4.1 (sample preparation), and 2.3.4.1 (Casein-agar plates).  
 
C.3. Results and Conclusions 
 
From the casein agar plates seen in Figure 68, it is possible to observe how 
Lactobacillus grown in MRS with 5% UHT milk did not develop proteases capable of 
casein hydrolysis since zones of clearance are not observed for most of the lactobacilli 
tested except for Bifidobacterium longum 15708 and slightly for Lactobacillus reuteri 
23272. 
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Plas minoge n precurs or (EC 3.4.21.7) [Contains: Plas min heavy chain A; Activation peptide ; Plasm in heavy chain A, short form ; Plasm in light chain B]. [Source:Uniprot/SWISSPROT;Acc:P06868]
68 unique  peptide s, 83 unique  spe ctra, 166 total spectra, 511/810 am ino acids (63% coverage)
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Figure 69: Casein-agar plates for analysis of caseinolytic activity of Lactobacillus grown 
in MRS-5%UHT milk.  
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APPENDIX D. Additional data corresponding to Chapter 2: Generation of 
angiostatin from bovine plasminogen hydrolysis by the action of Bacillus and 
Lactobacillus originated proteases 
 
D.1. Objective 
 
To determine different Bacillus growth and proteolytic enzymes generation 
between 12 and 24 hour incubation in TSB media at 37°C.    
 
D.2. Material and sources  
 
Bacillus spores were grown in TSB media at 37°C for 12 and 24 hours. 
Subsequently optical density as well as hydrolytic activity was analyzed to compare 
growth between different strains and incubation length effect. 
 
Strains analyzed: (classified based on observations made in previous experiments) 
High affinity: ATCC 23857, ATCC 14581, ATCC 8186  
Low affinity: ATCC 301, ATCC 4513, ATCC 23059 
High Angiostatin generation: ATCC 7050, ATCC 14579  
 
 
D.3. Results and Conclusions  
 
According to the optical density obtained in Table 10, it is possible to observe 
how the absorbance is significantly reduced after 24 hours growth compared to that seen 
after only 12 hours incubation in TSB media. This indicates that fewer bacteria are 
present after 24 hours. This phenomenon is most probably due to nutrients depletion that 
occurs after bacteria have reached a specific concentration. Moreover from the plates 
seen in Figure 69, the majority of the Bacilli analyzed show higher caseinolytic activity 
after being grown for 12 hours than after 24 hours. It is based on these observations that 
in our study bacillus were prepared by growing them in media for 12 hours.  
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Table 10: Optical density data obtained after 12 or 24 hours Bacillus growth in TSB 
media at 37°C (absorbance @ 686 nm (Colome et al. 1986)) 
Strain Optical density after 12h Optical density after 24h 
23857 0.500 0.150 
14581 0.528 0.360 
8186 0.351 0.163 
301 0.370 0.410 
4513 0.406 0.436 
23059 0.759 0.454 
7050 0.470 0.294 
14579 0.197 0.157 
Control (only media) -0.021 -0.022 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 70: Skim milk agar plates for hydrolytic analysis of Bacillus grown for 12 vs. 24 
hours in TSB growth media (plates were incubated at 37°C for 24h) 
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APPENDIX E. Additional data corresponding to Chapter 2: Generation of 
angiostatin from bovine plasminogen hydrolysis by the action of Bacillus and 
Lactobacillus originated proteases 
 
E.1. Objective 
 
  Identify fragments generated through bPG hydrolysis by the action of enzymes 
released from B.coagulans ATCC 7050 observed in Figure 41. 
 
E.2. Results and Conclusions 
From the sequence analysis data seen in Figures 70, 71, 72 and 73 no clear 
identification of the fragments generated was possible.  Perhaps various fragments with 
same molecular weight were generated, causing difficulty in identification of individual 
peptides present in the same band. In fact if we consider Figure 70, analysis of the data 
shows that for example 78% of kringle 1 of bPG is present, while 92% of K2, 100% of 
K3 and 45.5% of K5. On the other hand Figure 73 shows that only 60% of K1 is present, 
49% of K2, 52% of K3, 0% of K4 and only 20 % of K5. Based on this information it 
seems that Figure 70 covers more bPG than Figure 73, however the sequence of the 
peptide analyzed in Figure 73 has a much higher molecular weight than that in Figure 70. 
Based on these observations it is not possible to identify which fragments are generated 
from bPG by the action of B.coagulans ATCC 7050 generated enzymes through LCMS. 
Other methods of analysis are required in order to clarify what products are being 
generated from this reaction.  
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IPI00692205 (100%), 91,215.2 Da
Gene _Sym bol=PLG Plasm inogen
41 unique  peptide s, 46 unique  spe ctra, 91 total spectra, 395/812 am ino acids (49% coverage)
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17 unique  peptide s, 19 unique  spe ctra, 27 total spectra, 205/812 am ino acids (25% coverage)
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Figure 71: Sequence analysis of 22 kDa fragment generated through bPG hydrolysis by 
the action of B.coagulans ATCC7050. The colored amino acids represent the sequence 
coverage of bPG, and in green are observed post-translational modifications. (Sequence 
interpretation: K1: 78%  - K2: 91%  - K3: 100%  - K4: 71%  - K5: 45.5%)     
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 72: Sequence analysis of 25 kDa fragment generated through bPG hydrolysis by 
the action of B.coagulans ATCC7050. The colored amino acids represent the sequence 
coverage of bPG, and in green are observed post-translational modifications. (Sequence 
interpretation: K1: 82%  - K2: 44%  - K3: 54.5%  - K4: 0%  - K5: 20%) 
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IPI00692205 (100%), 91,215.2 Da
Gene _Sym bol=PLG Plasm inogen
13 unique  peptide s, 14 unique  spe ctra, 21 total spectra, 176/812 am ino acids (22% coverage)
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IPI00692205 (100%), 91,215.2 Da
Gene _Sym bol=PLG Plasm inogen
20 unique  peptide s, 22 unique  spe ctra, 32 total spectra, 244/812 am ino acids (30% coverage)
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Figure 73: Sequence analysis of 27 kDa fragment generated through bPG hydrolysis by 
the action of B.coagulans ATCC7050. The colored amino acids represent the sequence 
coverage of bPG, and in green are observed post-translational modifications. (Sequence 
interpretation: - K1: 63%  - K2: 56%  - K3: 31%  - K4: 0%  - K5: 0%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 74: Sequence analysis of 30 kDa fragment generated through bPG hydrolysis by 
the action of B.coagulans ATCC7050. The colored amino acids represent the sequence 
coverage of bPG, and in green are observed post-translational modifications. (Sequence 
interpretation: - K1: 60%  - K2: 49%  - K3: 52%  - K4: 0%  - K5: 20%) 
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APPENDIX F. Additional data corresponding to Chapter 4: In vitro digestion 
model 
 
F.1. Objective 
 
To determine lipase contamination through casein-SDS-PAGE 
 
 
 
F.2. Materials and Sources 
 
Casein-SDS-PAGE was prepared following procedures outlined by Fajardo-Lira 
and Nielsen (1998) with some modifications, and using the buffers which recipes are 
outlines in Table 11. Briefly, 20ul of each samples were prepared and 1:1 v/v Laemmli 
buffer was added without boiling. In order to allow SDS binding, samples were incubated 
at room temperature 30 minutes prior to electrophoresis.   
Prior to loading samples, casein-SDS-PAGE gel was pre-run at 200 V for 60 min 
to disperse the casein. Samples were then loaded and electrophoresis conducted following 
regular procedures. Once the proteins reach the bottom of the gel, the gel is removed and 
washed in casein-SDS-PAGE washing buffer to remove SDS, and subsequently 
incubated with casein-SDS-PAGE incubating buffer for 24 h.  At this point the molecular 
weight marker is removed and stored it in ddwater. The rest of the gel is stained and 
distained following regular procedures.    
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Table 11: Buffer recipes for casein SDS-PAGE 
 
 
F.3. Results and Conclusions  
 
Based on the CN-SDS-PAGE obtained in Figure 74, it is possible to observe 
contamination in lipase sample (lane 5), since lipase is not supposed to be able to 
hydrolyze casein, since it activity its lipid specific. Additionally, the enzymes seen in 
lipase sample seem to be the same observed in pancreatin samples known to contain 
proteases such as trypsin and chymotrypsin. Based on these observations, lipase was not 
used in our study.   
Sample description 15% resolving gel 4.5% stacking gel 
DDW (mL) 4.4 9 
Lower buffer (mL) 4.0 -- 
Upper buffer (mL) -- 3.75 
Acrylamide (40%) (mL) 4.8 1.35 
Glycerol (87%) (mL) 1.2 -- 
Casein (2%) (mL)* 1.6 -- 
TEMED (µL) 10 9 
Ammonium persulfate
 
(µL) 60 53 
* Add 0.2g Hammerstein Casein, 2.5 ml lower buffer, 7.5ml ddwater in a beaker 
and stir at 4°C for 30min/1h.   
 
SDS-PAGE Lower buffer (1.5 M Tris-HCl, 0.4% SDS) 
45.5 g Tris base 
10 mL 10% SDS  
200 mL DDW 
Adjust to pH 8.8 with HCl 
SDS-PAGE Upper buffer (0.5 M Tris-HCl, 0.4% SDS) 
15.1 g Tris base 
10 mL 10% SDS 
200 mL DDW 
Adjust to pH 6.8 with HCl 
 
Casein SDS-PAGE Washing buffer (2.5% Triton X-100) 
22.5 mL Triton X-100 
877.5 mL DDW 
Casein-SDS-PAGE Incubating buffer (0.05 M Tris-HCl buffer, 0.1 M NaCl) 
6.04 g Tris base 
5.84 g NaCl 
Dilute to 1 L with DDW 
Adjust to pH 7.6 with HCl 
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Figure 75: Casein SDS-PAGE for analysis of lipase contamination. Lane 1: MW 
standard; lane 2: cathepsin-D control; lane 3: pepsin; lane 4: bile; lane 5: lipase; lane 6: 
pancreatin   
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